Podcasts about American Diabetes Association

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: T1D in the Olympics & Superbowl, Trump RX goes live, Ozempic pill available soon, tech updates from Medtronic, Beta Bionics, Eversense 365 and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: We are just over one week from our first Moms' Night Out event of the year. While the plans are all set – the speakers, the vendors, the raffles and the fun is ready to go, it's always amazing how many people hear of these event last minute. That's fine, they're welcome! But if you're thinking of attending a future event – registration is open for We're going to Nashville next March 6-7 and Detroit in September – no need to wait. And we've got Club 1921 events for health care professionals and patient leaders in 6 cities this year! All the info is over at diabetes-connetionss.com events/   Okay.. our top story this week: XX Gotta be a quick shout out to some incredible T1D athletes – we had TWO in the super bowl this past weekend – Chad Muma of the New England Patriots and Logan Brown of the Seattle Seahawks AND there are at least two athletes with type 1 competing at the Winter Olympics. Hannah Schmidt competes in ski cross for Canada – she was diagnosed with Type 1 diabetes at age 12 years old.  Anna FarnSchadt Fernstäd a Czech skeleton racer diagnosed in 2022 after she'd already been to several Olympics. We wish them all the best!   https://english.radio.cz/skeleton-racer-anna-fernstadtova-overcoming-adversity-headfirst-down-ice-8876699 XX The government website TrumpRx.gov is live..  the website does not sell prescription drugs. Instead, it allows people to look up their drugs and then navigate to buy them elsewhere, either from a major drug company or a pharmacy. The 43 drugs listed on the site have prices ranging from $3 to over $5,500. TrumpRx does include warnings that the site may not be the best option to save money on prescriptions. Each product page advises: "If you have insurance, check your co-pay first — it may be even lower." For now, the website says its prices are for people paying with their own money, rather than going through insurance. The only insulin listed right now is Lilly's insulin lispro – and it's the same price as you'd find through Illy's insulin value program. I looked up diabetes meds.. For example, if you have an insurance co-pay of $25 a month for Farxiga, a drug often used for diabetes, you would be paying $182 on TrumpRx. As you can imagine, though ,this is complicated and as with most of our healthcare system, it may be good in some cases and not much help in other.  I'd suggest calling your local pharmacist or checking with your human resource dept. https://www.nytimes.com/2026/02/06/health/trumprx-prescription-drug-prices-consumers.html XX Novo Nordisk will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year. The company said the U.S. Food and Drug Administration has approved Ozempic tablets in three different doses. Novo says The new Ozempic name is intended to help patients and health care professionals more easily recognize the available treatment options for type 2 diabetes Semaglutide tablets have been available under the brand name Rybelsus Ruh BELL sis for diabetes since 2019 but with different dosing. The pill is also approved to reduce the risk of certain cardiovascular conditions in adults with type 2 diabetes who are at high risk for these events. The FDA had approved the new doses based on a bioequivalence study and the clinical trial data for Rybelsus, Novo said. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-launch-ozempic-pill-diabetes-second-quarter-this-year-2026-02-04/ XX https://www.contemporarypediatrics.com/view/early-screening-for-type-1-diabetes-found-effective-in-children XX Possible new way to identify and track the progress of type 1 diabetes before clinical onset. A recent study published in Science Advances described the application of subcutaneous microporous scaffolds. These are inserted and have been shown to  identify changes in cancer, multiple sclerosis, and T1D by capturing changes of immune cells over the course of a disease. This is a proof of concept study in mice.. so very early days. https://www.news-medical.net/news/20260204/Implantable-immune-scaffold-predicts-type-1-diabetes-weeks-before-symptoms.aspx XX A large global genetics study shows that many key drivers of Type 2 diabetes operate outside the bloodstream. In a major international project led in part by the University of Massachusetts Amherst and Helmholtz Munich in Germany, researchers linked hundreds of genes and proteins to the disease. The work, published in Nature Metabolism, points to a key challenge in diabetes research: the biology behind rising blood sugar does not play out the same way in every part of the body. It also shows why including people from many backgrounds matters, since genetic clues that stand out in one population may be faint or invisible in another. Huge study, 2.5 million people worldwide comparing patterns across seven tissues tied to diabetes and four global ancestry groups, then asked a simple question: what do you miss if you only measure blood? Across the seven tissues, the researchers found causal evidence pointing to 676 genes. Yet overlap with blood was limited: only 18% of genes with a causal effect in a primary diabetes tissue, such as the pancreas, showed a matching signal in blood. At the same time, 85% of genetic effects observed in diabetes-relevant tissues were completely absent from blood-based analyses. The findings lay out a roadmap for future research aimed at understanding the biological pathways underlying Type 2 diabetes and developing more effective treatments. https://scitechdaily.com/massive-global-study-rewrites-the-biology-of-type-2-diabetes/ XX Express Scripts settled the U.S. Federal Trade Commission's claims its insulin pricing practices violated antitrust and consumer protection laws, and agreed to changes aimed at lowering costs for patients, insurers and small pharmacies The settlement, first reported by Reuters, fits with that goal, and allows the FTC to pare down a case brought by the former Biden administration against Cigna's Express Scripts, UnitedHealth Group Inc's (UNH.N), Optum unit and CVS Health Corp's (CVS.N), CVS Caremark. The case against Optum and Caremark is ongoing. Pharmacy benefit managers, which set how drugs are covered by health insurance, have faced a decade of scrutiny from regulators and lawmakers over pricing practices. While the industry has already made reforms, the settlement gives the FTC power to enforce broader changes at Express Scripts. The 10-year agreement restricts Express Scripts' ability to engage in practices critics say contribute to high costs, like pocketing rebate payments from drugmakers based on the list price of drugs. The FTC estimates the agreement could save patients as much as $7 billion over a decade. https://www.reuters.com/world/cigna-settles-ftc-insulin-case-commits-overhauling-drug-pricing-2026-02-04/ XX Audio? Congress has passed bipartisan legislation to extend and strengthen the Special Diabetes Program (SDP), a cornerstone of Federal investment in type 1 diabetes (T1D) research. The President signed the legislation and it is now law. Extends the SDP through December 31, 2026, and increases funding from $160 million to $200 million annually. Strengthens overall funding for the National Institutes of Health (NIH) by $415 million. Increases diabetes research funding at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) by $10 million. Created by Congress and administered by the NIH, the SDP has contributed nearly $3.6 billion to T1D research and has played a role in nearly every major breakthrough in the field. A recent study conducted by Avalere Health shows that of the nearly 3.6 billion invested into the SDP by Congress since the establishment of the program, the Federal Government has realized $50 billion in healthcare savings through improved health outcomes from the use of SDP driven therapies and devices https://www.breakthrought1d.org/news-and-updates/congress-passes-bipartisan-extension-of-the-special-diabetes-program-securing-critical-t1d-research-funding/ XX Dexcom is rolling out what they're calling AI-enabled enhancements to Stelo, further transforming how users track and understand their glucose health. Expanded Smart Food Logging including a comprehensive nutrition database of more than 1M meals that provides a breakdown of calories, carbohydrates, protein, fat, dietary fibers, and more. More ways to meal track including text search, barcode scanning or taking a photo of the meal, creating a seamless and intuitive meal tracking solution. A redesigned Daily Insights feature which will introduce a new interface with more personalized recommendations. The newest features will launch nationwide in the coming weeks.  XX Beta Bionics has received a warning letter from the Food and Drug Administration following an inspection last year, the company disclosed on Friday. The diabetes technology company said in a securities filing that the warning letter concerns non-conformities with the company's quality management system, medical device reporting, and correction and removals. The warning letter has not yet been posted by the FDA.   The company said in the filing that it has already taken actions to improve the processes described in the warning letter, and it is working on a written response to the FDA.   The firm does not expect the warning letter to affect the planned launch of a new insulin patch pump by the end of 2027. Beta Bionics unveiled a prototype of the device, called Mint, last year at the American Diabetes Association's Scientific Sessions. The company also does not expect the warning letter to affect its financial results. https://www.medtechdive.com/news/beta-bionics-receives-fda-warning-letter/811140/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue%3A+2026-02-04+MedTech+Dive+%5Bissue%3A81423%5D&utm_term=MedTech+Dive&fbclid=IwY2xjawPwhDZleHRuA2FlbQIxMABicmlkETFaUUcyYmNQWldjZ2xudElic3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHouF8M3IstTyslPRgeHWUWVVdOAGOtzPWt_yNFcj9eYruqSPz3e86Iwcbpt8_aem_7q4D97vJVjHKfEwvoyUpgw XX Sequel Med Tech is reviewing co-founder Dean Kamen's ties to Jeffrey Epstein after recently released documents revealed new details about the longstanding relationship between the two men. The documents show that Kamen visited Epstein's island, and remained in contact with him for years after Epstein was convicted of sex crimes involving minors. Kamen has not been accused of any wrongdoing. In a statement, Sequel Med Tech said the Manchester-based company is aware of the documents pertaining to Kamen and – quote - "Sequel's Board of Directors has unanimously decided to engage an external law firm to review these disclosures and provide recommendations aligned with our mission to serve people living with diabetes," Kamen has not issued a statement regarding his reported connection to Epstein.   https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ https://www.nbcboston.com/news/local/nh-inventor-placed-on-leave-after-epstein-messages-surface-report-says/3888569/ XX Abbot reports 860 serious injuries linked to the recall of some of its glucose monitoring sensors. We told you about this recall late last year, these numbers are an FDA update.     Abbott said the sensors can provide incorrect glucose readings over extended periods, which could lead to users making dangerous treatment decisions, including eating excessive carbohydrates along with skipping or delaying insulin doses, potentially leading to serious health risks. The company said it has identified and resolved the cause of the issue, which relates to one production line among several that make Libre 3 and Libre 3 Plus sensors.   https://www.reuters.com/business/healthcare-pharmaceuticals/abbott-recalls-glucose-sensors-after-seven-deaths-linked-faulty-readings-2026-02-04/ XX Updates from Medtronic & Senseonics – and a first from Nick Jonas.. right after this..   I'm excited to share that the FDA has cleared the MiniMed 780G system with the Instinct sensor, made by Abbott, for people with type 2 diabetes.  Medicare has also now approved coverage for the Instinct sensor for use with the MiniMed 780G system. This clearance and expanded coverage mean more people will have access to pairing our most advanced automated insulin delivery technology with the Instinct sensor, that offers a smaller, 15-day sensor experience.  They're also launching the MiniMed 780G system Pump Evaluation Program.  This program gives individuals living with diabetes the ability to try the full MiniMed 780G system at no cost for 30 days.† This includes the pump, the sensor of their choice, one month of infusion sets and reservoirs, everything but the insulin. They'll contact your doctor for you to get a prescription and get the process rolling. https://www.medtronicdiabetes.com/pump-evaluation-program XX Senseonics announced today that its Eversense 365 continuous glucose monitor (CGM) system received CE mark approval – that's European clearance.  This comes on the heels of the launch of Eversense 365 with Sequel Med Tech's twiist pump, marking the first pump integration for the CGM. Senseonics plans to launch Eversense 365 in Germany, Italy, Spain and Sweden in the coming months. Meanwhile, Senseonics continues to work toward an FDA investigational device exemption (IDE) submission for its next-generation Gemini transmitter-less CGM by the end of this year. https://www.drugdeliverybusiness.com/senseonics-ce-mark-eversense-365-cgm/ XX A huge shout out to Dr. Emily Blum, who just accomplished riding 100 miles in Antarctica for Breakthrough T1D! Despite having no direct connection to Type 1 Diabetes, Emily has been riding and fundraising for BreakthroughT1D for 10 years now. She is an integral part of the Georgia Ride team, training and riding many miles, and most importantly has raised tens of thousands of dollars to support the cause of ridding the world of T1D. She is surgeon and deeply involved with medical innovation, with an incredibly busy schedule, but jumped at the chance to take on the challenge of riding a century on every continent. Having already completed North America, Europe, Australia, Asia, and now Antarctica, only Africa and South America remain. Emily rides on and continues to be an inspiration to everyone who meets her. XX   https://diabetes-connections.com/t1d-connection-and-people-magazine-elise-zach-share-their-story/ XX Nick Jonas's becomes the first artist ever to wear a CGM on an album cover - new upcoming solo album Sunday Best, releasing Feb. 6.  The release says: This marks a powerful step forward in normalizing diabetes and raising awareness for the condition on a global scale. This moment adds to the growing visibility of diabetes in pop culture, alongside milestones like a Type 1 diabetes Barbie and Pixar characters wearing diabetes technology.

Kiera is joined by the tooth-healer himself, Jason Dent! Jason has an extensive background in pharmacy, and shares with Kiera where his pharmaceutical experience has bled over into dentistry. This includes the difference between anti-quag and anti-platelet and which medications are probably safe, what to do to shorten the drag time in the pharmacy, how to write prescriptions most efficiently, and more. Episode resources: Subscribe to The Dental A-Team podcast Schedule a Practice Assessment Leave us a review Transcript: The Dental A Team (00:00) Hello, Dental A Team listeners. This is Kiera and today is a really awesome and unique day. It is, think the second time I've had somebody in the podcast studio with me live for a podcast and it's the one and only Jason Dent. Jason, how are you? I'm doing well. Good morning. Thanks for having me. It is crazy. I I watch Instagram real like this all the time where people are like in the podcast and they're hanging out on two chairs and couches and now look at us. We're doing it. Cheers. Cheers.   That was a mic cheer for those of you who are only listening, but yeah, Jace, how does this feel to be on the podcast? It's weird. Like I was not nervous at all talking about it. I got really nervous as soon as you hit play. So if I stumble over my words, please forgive me ahead of time. Well, Jason, I appreciate you being on the podcast because marketing had asked me to do a topic about teledentistry and I was like, oh shoot, that's like not my forte at all. so   You and I were actually chatting in the hot tub. call it Think Tank session and you and I, we have a lot of good ideas that come from that Think Tank. A lot of business. no phones. That's why. We do leave our phones out. But I was talking to Jason and this is actually a podcast we had talked about quite a while ago. Jason has a lot of information on pharmacy. And if you don't know, Jason isn't really, we were going through all of it last night. It's kind of a mock in the tub. And I think it's going to be great because I feel like this is an area, I'm working at Midwestern and   knowing about how dentists, pharmacology was surely not your favorite one. Jason actually helps a lot of dentists with their clearances. And so we were talking about it and I like it will just be a really awesome podcast for you guys to brush up on pharmacology, different things from a pharmacist's side. So Jason, welcome. Thank you. Yeah, no, we were talking about it and here's like, what should I talk about on the podcast next? I have all these different topics and she's like, what do you know? And the only real interaction I have with dentists is doing clearances for procedures. We get them all the time, which makes sense.   Lots of people are on blood thinner, I've always told Kiera, like, hey, I could talk about that. Like, that's kind of a passion of mine. I'm not a dentist. Or my name is Jason Dent. So in Hebrew, Jason means tooth. No, no, no, sorry. Nerves are getting to me. Jason means healer and Dent means tooth. So my name means tooth healer. So, here's a little set. Hold on, on, hold Can we just talk about? I brought that up before you could talk about it more. So.   My name means tooth healer but I did not become a dentist. I know you wanted me to become a dentist. did. I don't know why. I enjoy medicine. I know what you're going to get to already. The things you're going to ask me. There's been years of this. But nevertheless, that's my name. We'll get that out of the way. But you did give me a great last name. So I mean, it's OK. You're All is fair and love here. SEO's up for that. But yeah, Jason, I'm going to get you right into the show. And I'm going to be the host. And we're going to welcome to the podcast show. Jace, how are you?   Good, good, good. Good, good, good. So by getting into clearances, right? This is what you're kinda talking about with you know, before we get to clearances, I actually wanted Jason, for the listeners who don't know you, who haven't talked to you, who don't know, let's kinda just give them like, how did you go from, Kiera wanted you to be a dentist, to now Jason, you are on the podcast talking as our expert on pharmacy. fantastic. I've always really loved medicine, a ton. As a kid getting headaches and taking Excedrin, like you just feel like a miserable pile of crap.   and then you take two pills and all of a sudden you feel better. Like that's amazing, like how does that happen? Also getting ear aches as a kid, just being in so much pain and then taking some medicine and you start feeling a lot better. I always had a lot of appreciation for that. I've always been mechanically inclined. I went to, started doing my undergrad and took biology and learned about ATP synthase, which is a spinning enzyme that's inside the mitochondria, like a turbine engine. I used to work on small engines on my dirt bike and thought that is so cool. So I really got wrapped up into chemistry.   All the mechanics of chemistry really pulled me in. I'm not getting goosebumps. checking. I usually get goosebumps when I think about chemistry. But it's so cool. You think an engine's awesome, like pistons and camshafts and pressures, the cell is the same thing. It's not as loud, so it's not as cool. But it's fascinating. that's why we're like. ⁓   chemistry and really got into coagulation. So I did my residency after pharmacy school. we went to Arizona for three years. ⁓ You did and your main focus, you were never wanting to be the guy behind the counter. No, I haven't done that. Yeah. No, I love them though. I've always really want to go clinical. ⁓ But I love my retail ⁓ pharmacists. They're amazing resources. And ⁓ I use the retail pharmacist every day still to this day, but I went more the clinical route, really love the chemistry aspect of it.   did my doctorate degree and then I did my residency in Reno. Reno's kind That's how we got here everybody. Welcome to Reno. Strategically placed because I was really interested in critical medicine and where we're located we cover a huge area. So we pull in to almost clear, we go clear to Utah, clear to California, all of Northern Nevada. We get cases from all over. So we actually are kind like the first hub of care for lot of areas. So we really get an eclectic mixture of patients that come in that need-   all kinds of different cases that are coming to them. So it's what I really wanted. So I did my residency in critical care there. And then for the next 10 years, I worked in vascular medicine with my final five years being the supervisor of the clinic. Ran all the ins and outs of that. So my providers, two doctors were on our view. So when we talk about dentistry, talk about production, those kinds of things, totally get it. My doctors were the exact same way, my vascular providers. ⁓   There's some pains there, right? You wanna be seeing patients as much as possible, being able to help as many people, keeping the billing up. And had other nurse practitioners, four practitioners, a fleet of MAs, eight pharmacists. We also had that one location we had, going off the top of my head, I think we had eight locations running as well. And we took care of all the different kinds of vascular cases that came to us. Most common was blood clots, ⁓ which is just a...   which is an easier way of saying VTE. There's so many different ways to say a blood clot. Like you might hear patients say, I've had a PE or a DVT or a venous thromboembolism or a clot in my leg, right? They're all clots, but in different locations. Same with an MI, and MI can be a clot as well. ⁓ there's a lot of, everybody's kind of saying the same thing, but sometimes the nomenclature can make it sound hard, but it really is actually pretty simple.   No. And Jason, I love that you went through, you've been in like, and even in your, ⁓ when you were getting your doctorate, you were in the ER. You also worked in retail pharmacy. remember you having a little sticker on your hand. And retail pharmacy, I have a lot of respect for those guys. They have a lot of pressure on them. and then you also, ⁓ what was that test that you had to take that? I don't know. You were like studying forever for it. ⁓ board certification for, ⁓ NABP. Yeah. So I did that board certification as well.   And now you've moved out of the hospital side onto another section in your career. Now in the insurance, right? So it's really, really interesting. So now I'm on the other side reading notes and evaluating clinical appropriateness and trying to help patients with getting coverage and making those kinds of determinations. So yeah, I've really jumped all over. Really love my clinical days. I know. don't I don't I do miss them. But yeah, kind of had a good exposure to a lot of.   pharmacy a lot a lot of dentists actually with all the places that come through which Jason I really appreciate that and honestly I know you are my spouse and so it's fun to have you on but when I go into conversations like this I don't know any of this information and so finding experts and Jason I think here's me talk more about dentistry and my business than I do hear about him on pharmacy so as we were chatting about this I really realized you are a wealth of knowledge because you've been on the clinical side so you've done a lot of patient care and you've seen how   medications interact and I know you've had a few scares in your career and ⁓ you've known some physicians that have had a few scares and ⁓ you've seen plenty of patients pass away working in the ER and gosh in Arizona drownings were such a big deal. I remember when you were in the ER on your rotations I'd be like who died today? Like tell me the stories and you've really seen and now going on to the insurance side I felt like you could just be such a good wealth of knowledge because I know dentists are sometimes so   I would say like maybe just a little more anxious when it comes to medications. I know that dental students from Midwestern were like here was like four months and we had to like pass it, learn it. And Jason, you've done four years plus clinical residency, plus you've been in it. And something I really love about Nevada Medicine is they've been so collaborative with you.   like your heart, your cardiologist, they diagnose and then they send to you to treat with medicine and... Yeah, I've been really lucky being here in Reno too. The cardiology team has been amazing to work with. We started a CHF program, sorry, congestive heart failure program for patients. So we would collaborate with cardiologists. They'd see the cardiologists and then they send them to the pharmacist to really manage all the medications. So there's pillars of therapy ⁓ called guideline directed medical therapy and the pharmacist would take care of all that. So that's gonna be your...   your beta blockers, your ACEs, your ARBs, your Entresto, which would be a little bit better, spironolactone. So just making sure that all these things are dosed appropriately, really monitoring the heart, and make sure that patients are getting better. we've had real positive outcomes when the, sorry, this is totally off topic. do, talk about that study. When we looked at when patients were coming to see our pharmacists in our clinic that we started up, the patients were half as likely to be readmitted. And this was in 2018, and our pharmacists,   We're thinking about all the medications. We're usually adjusting diabetes medications too at the same time. Just kind of naturally just taking care of all the medications because we kind of got a go ahead from the providers, a collaborative practice agreement that we could make adjustments to certain medications within certain parameters. So we weren't going rogue or maverick, but we were definitely trying to optimize our medications as much as possible. And then years later, some studies came out with, I'm sure you've seen Jardins and Farseegh. not trying to, I'm not.   I don't get any kickback from them. I have no conflicts to share. But because our pharmacists were really optimizing that medication, those medications were later shown to reduce hospitalizations and heart failure, even though they're diabetes medications. Fascinating. So it wasn't really the pharmacists. It was just the pharmacists doing as much as they can with all the tools that were in front of them. And then we found out that the patients were going back to the hospital.   half as much as regular patients. So, yeah, being here, it's been so amazing to work with providers here. the providers here want help, want to help patients, don't have an ego. I mean, I just, it's awesome. I love it. I do love how much I think Jason sees me geek out about dentistry and I watching Jay's geek about his pharmacy and how much he loves helping patients. And ⁓ really that was the whole idea of, all right.   Dentistry has pharmacy as a part of it. And I know a lot of dentists are sending in clearances and I know working in a chair side, it would be like, oh no, if they're on warfarin or on their own blood clot, you guys, honestly don't even know half of what I'm talking about because this is not my jam, which is why Jason's here. But I do know that there was always like, well, we got to talk with their provider. And so having Jason come in and just kind of explain being the pharmacist that is approving or denying or saying yes or no to take them off the blood thinners in different parts, because you have seen several dental   I don't know what they're called. What is it? Clarence's? that what comes to you? don't even know. All day my mind, it's like, here is the piece of paper that gets mailed to you to the pharmacist and then you mail it back. So whatever that is. But Chase, let's talk about it because I think you can give the dentist a lot of confidence coming from a pharmacist. What you guys see on that side. When do you actually need to approve or disapprove? Let's kind of dig into that. Yeah. Well, first of all, I think I'm not a replacement for any kind of clinical judgment whatsoever. Every patient's different. But the American Diabetes Association, you   I work with diabetes a lot. American Dental Association has some really great guidelines on blood thinners and I would always reference them. I actually looked at their website today. Make sure I'm up to speed before I get back on this again. They have resources all around making decisions for blood thinners. And I think the one real important thing in putting myself in the shoes of a dentist or any kind of staff that's around a patient that's in a chair, if they say I'm on a blood thinner, right, a flag goes up. At least in my mind, that's what goes up.   Like, okay, how do we get across this bridge? And I think the important thing to really distinct right then when they say they're on a blood thinner is that is kind of a slang word for a lot of different medications, right? Like it's the overarching word that everybody pulls up saying, I'm on a blood thinner. It's like, okay, but I don't know what say. It's like, I have a car. You're like, okay, do you have a Mazda? Do you have?   Toyota, Honda, what do you have? or even worse it'd be like saying I have a vehicle, right? So when somebody says they're on a blood thinner, it opens up a whole box of possibilities of what they're Blood thinners are also, doesn't, when they're taking these types of medications that are quote unquote a blood thinner, it doesn't actually thin the blood, like adding water to the blood, if that makes sense, or like thinning paint, or like thinning out a gravy, right? It doesn't do the same thing. Blood thinners, really what they're doing is they're working on the blood, which.   which is really cool, try not to tangent on that. ⁓ When they're working on the blood, it's not thinning it per se, but it's making it so that the proteins or platelets that are in it can't stick together and make a cloth quite as easy. So whenever somebody's on a blood thinner, I usually ask, what's the name of the blood thinner that you're on? It's not bad that they use that slang, that's okay, on the same page, but it's really broken into two different classes. There's anticoagulant and antiplatelet.   And a way to kind of remember which is which, when residents would come through our clinics, the way that I teach them is a clot is like a brick wall. You know, it's not always a brick wall. Usually the blood is a liquid going through. But once they receive some kind of chemical message, it starts making a brick wall with the mortar, which is the concrete between the and the bricks, the two parts. When it's an anti-quagent, it's working on that mortar part. When it's an anti-platelet, it's working on the bricks part, right? You need both to make a strong clot or strong brick wall.   But if you can make one of them not work, obviously like if your mortar is just water, it's not working, right? You're not gonna make a strong brick wall. So that's kind of the two deviants right there. So that's what I do in my mind real quickly to find out because antiplatelets are usually, so that's gonna be like your Plavix, Ticagrelor, Brilinta. And hold on, antiplatelets are bricks? Good job, bricks. They're the bricks. And so the reason I was thinking you could remember this because I'm, antiplatelets, it's a plate and a plate is more like a brick.   And anti coagulant, I don't know why quag feels like mortar to me, like quag, like, know, it's like slushy in the blood, like it's coagulating. It's a little bit of that, like, honestly, I'm just thinking like coagulated blood is a little bit more mortar-ish. And so platelet is your plate, like a brick, and anti-quag is like.   the gilly between the bricks. Okay, okay, I got it. Yeah, so there's an exception to every rule, but when they're on that Don't worry, this is Kiera, just like very basic. You guys are way smarter listening to this, and that's why Jason's here. No, no, you helped me pass pharmacy school. When we were doing all the top 200, you helped me memorize all know what flexorill is, all right? That's a muscle relaxant. Cyclo? I don't know that part. It's a cyclo, because you guys are cycling and flexing. I don't actually know. just know it's a muscle relaxant, so that's about as far as I got. When we're looking at antitick platelets, so that's the brick part, so that's going to be your, you know,   Hecagrelor, Breitlingta, Clopidogrel is the most common one. It's the cheapest one, so probably see that one the most. Those, I mean, there's an exception to every rule, but that's generally being used after like a stent's placed in the heart. It can be used for VTE, there's some out there, but that's pretty rare. But also for some valves that are placed in the hearts, it can be used for that as well. So antiplatelet, really thinking more like a cardiac event, right? Like I said, there's always an exception to every rule, but that's kind of where my mind goes real quickly, because we're gathering information from the patient.   They're on anticoagulant. Those are like going to be the new ones that you see commercials for all the time. So Xeralto, Alequis, those are the two big ones right now. They're replacing the older one. And also we were supposed to do a disclaimer of this is current as of today because the ADA guidelines do change. this will be current as of today. And Jason, as a pharmacist, is always looking up on that. I had no clue that you are that up to speed on dental knowledge. so just throwing it out there that if you happen to catch his podcast,   a few years back that obviously check those guidelines for sure. But the new ones are the Xarelto and Eloquist. They're replacing the older ones of warfarin. Warfarin's been around for a really long time. We've seen that one. Those are anti-coagulants. So when you're looking, when a patient says that, generally they're on that medication because they've possibly had a clot in the past or they have a heart condition called atrial fibrillation. Those are kind of the two big ones. Like I said, there's always caveats to it, but that's kind of where my mind goes real quickly. And then,   as far as getting patients cleared, the American Dental Association has really good resources on their website. You can look at those and they're always refreshing that up. They even say in their own words that there's limited data around studying patients in the dental chair and with anticoagulants or anti-platelets. It's pretty limited. There's a few studies, some from 2015, some from 2018. There's one as recent as 2021, which is nice. But really, all of those studies come together and it's really more of an expert consensus.   And with that expert consensus, they have kind of simplified things for dentistry, which is really nice. ⁓ comparing that to, we have more data for like total hip replacement, total knee replacement. We have a lot of data and we know really what we should be doing around then. But going back to dentistry, we don't have as much information, so they always say use clinical judgment, but they do give some really great expert guidance on that. So if a patient's on an anticoagulant, ⁓   they generally recommend that it doesn't need to be stopped unless there's a high bleeding risk for a patient. as a provider or as a clinician in the practice, you can be looking at high bleeding risk. Some things that make an oral procedure a little bit lower risk is one, it's in the compressible site, right? Like we can actually put pressure on that site. That's the number one way to stop bleeding is adding pressure. It's not like it's in the abdominal cavity where we can't get in and can't apply pressure. So number one, that kind of reduces the bleeding risk.   is number one. Two, we can add topical hemostatic agents. Dentists would know that better than me. There's a lot of topical ways to do that. So not only pressure, but there's those things as well. And also, but there are some procedures that are a little bit more likely to bleed. And that's where you and dentists would come in hand in What's the word in APO? Oh, the APOectomy. I got it right. Good job. like, didn't you tell me last night that the ADA guideline was like what?   three or four or more teeth? great question. So you can extract one to three teeth is what their expert consensus One to three teeth without. Without really managing or stopping anticoagulation or doing anything like that. I think that's some good guidance from them. I'm gonna add a Jasonism on that though. So with warfarin, I do see why dentists would be a little bit more conservative or worried about stopping the warfarin because warfarin isn't as stable as these newer agents. Warfarin, the levels.   quote unquote levels can go really high, they can go really low. And if the warfarin levels are high, they're more likely to bleed. So I do think it makes sense to have a really recent INR. That's how we measure what the warfarin's doing. I think that makes a lot of sense, but the ADA guidelines really go into the simplification version of all these blood thinners. Generally, it's recommended to not stop them because the risk of stopping them outweighs the benefit of stopping them in almost every case. Almost every case.   ⁓ So when you're with that patient, right, they say I'm on a blood thinner, finding out which kind of blood thinner that they're on, you find out that they're on Xeralto, right? How long have you been on Xeralto for? I've been on it for years. You don't know exactly why, but if they haven't had any recent bleeding, you're only gonna remove one tooth. ⁓ You can do what's called a HasBlood score. That kind of looks at the bleeding risk that they'd have. That'd be kind of going a notch above, but in my mind, removing one tooth isn't a real serious bleeding risk. I'd love to hear from my dentist friends if they...   disagree, right, but ADA says one to three tooth removals, extractions, that's the fancy word. Extractions, yeah, for extracting teeth out. Is not really that invasive. Sure. It's not that high risk, so it's usually perfectly fine. So if a patient was on Xarelto, ⁓ no other, this is in a vacuum, right? I'm not looking at any other factors, which you should be looking at other factors. I would be perfectly fine to just remove one to two.   And when those clearances come in, because dentists do send them, talk about what happens. You guys were working in the hospital and you guys would get these clearances all the time. do. We get them so often. I mean, we get like four or five a day. We'd love to give it to our students, student pharmacists, and ask them what to do. And they would usually look up the American Dental Association guidelines and come up with something. We're like, yep, that's what we say too. In fact, we say it so many times a day that we have a smart phrase.   which just blows in the information real quickly and faxes it right back to the So it's like a copy paste real quick. So what I wanted to point out when Jason told me this is dentists like hearing this and learning this, this can actually save you guys a ton of time to be able to be more confident, to not need to send those clearances on. And we were actually talking last night about how I think this might be a CYA for dentists. like, as we were talking, I think Jason, you seeing so many other aspects of medicine, like you've literally seen patients die, you've seen other areas.   And so coming from that clinical vantage point, we were realizing that dentists, we are so blessed to live in an injury. I enjoy dentistry because possibly there's someone dying, not super high, luckily in dentistry. The only time that I have actually had a doctor have a patient pass away, and it was only when they were completely sedated and doing ⁓ some other things, but that was under the care of an anesthesiologist. And so that's really our high, high risk. And so hearing this, Jason,   That was one of the reasons I wanted him to come on is to give you doctors more confidence of do we have to always send to a pharmacist? I mean, hearing that on the pharmacy side, they're just sending these back and not to say to not see why a to not cover this because you might be questioning like, well, do I really need to? But you also were talking about some other ways of so number one, you guys are just going to copy back the 88 guidelines. So so 88 guidelines. Yeah. And I think that that gives a lot of confidence to a provider or a dentist is that you can go to the 88 guidelines and read them, right? Like you're listening to some   nasally monotone pharmacist on a podcast. Rumor has it, people love him at the hospital. were like, you're the voice, he's been told he has a good radio So for the clinic, I was the voice. Like, yeah, you've reached the vascular clinic, right? And they're like, oh my gosh, you're the voice. But sorry, you me distracted. That'll be your next career, Jace. You're going to be a radio host. OK. I would love that. I love music. But you're hearing from a nasally guy, but you can actually read the ADA guidelines. You just go right to the ADA, click on Resources, and under Resources, it has the   around anticoagulants, I think that's the best way to get a lot of confidence about it because they have dentists who are the experts making calls on these. I'm just reiterating what they say, but I think it makes a lot of sense to help providers. And the reason why my heart goes out to you as well is having the providers that used to work underneath me, they're always looking for our views, which is a fancy way of making sure that they're drilling and filling. Can I say that? Yeah, can say drilling and filling. They're being productive, right? They're being productive, right?   They're always looking to make sure if a patient's canceling, like get somebody in here. Like I need to be helping people all day long. That's how I, we keep the lights on. That's how I help as many people. And so if you have a patient coming in the chair and it has an issue, they say I'm on Xeralto. Well, you can ask real quickly, why are you on Xeralto? I had a clot 10 years ago. my gosh. Well, yeah, we're pretty good to go. Then I'm not worried. We're only removing one tooth or we're just doing a cavity or a cleaning. Something like that. Shouldn't be an issue whatsoever because there's experts in the dental. ⁓   in the dental society, the ADA guidelines that recommend three teeth or less, minimally invasive. They really recommend if it's gonna be really high bleeding risk. And clinically, that's where you would come in, ⁓ or yourself. know, apioectomy is one that's like on the fence line. I don't know where implants set. though, and like we were talking, implants aren't usually like a date of procedure. Most people aren't popping in, having tooth pain, and we're like, let's do an implant. Now sometimes that can be the case, but typically that one's gonna have   a few other pieces involved. And so that is where you can get a clearance if you want to. ⁓ But we were really looking at this of like so many dentists that I know that you've seen will just send in these clearances because they are. And I think maybe a way to help dentists have more confidence is because you know, I love routines. I love to not have to remember things. So why don't we throw it in, have the team member set it up where every quarter we just double check the ADA guidelines. Are there any updates? Are there any other things that we need to do on that? That way you can just see like   getting into the language of this, of what do I need to do? Because honestly, you guys, know pharmacy was not a big portion for it, so, recommending different parts, but I think this is such a space where you can have confidence, and there's a few other things I wanna get to, and I you- I some pearls too. Okay, go. I'm so when she get me into talking about drugs, I'm not gonna stop. So, some other things around that too is these newer blood thinners like Xarelto Eloquist, they now have reversal agents, so a lot of providers in the past were really worried about bleeding because we can't turn it off. We can turn those off. Warfarin has reversal as well, right?   So I'm looking at these patients. It's really low risk. It's in the mouth, generally speaking. Very rarely are they a high bleeding risk. Now if you're doing maxillofacial surgery, this does not apply, right? This does not apply whatsoever. you're like general dentist, you're pediatric dentist. Yeah, yeah, and it's kind of on the fly. So just trying to really help you to be able to take care of those patients on the moment, have that confidence, look at the ADA guidelines, have that in front of you. I don't think it's a bad thing to ever...   check with their provider if you need to. If you're thinking, I feel like I should just check with the provider, I would never take that away from you. But I just want to kind of steer towards those guidelines that I have to help. But what did you want to share? No, yeah, I love that. And I think there were just a few other nuggets that we were chatting about last night that can help dentists just kind of get things passed a little bit easier. So you were mentioning that if they were named to their cardiologist, what was it? was like, who is the last? Great question. Yeah, when a patient's on a blood thinner,   It could be prescribed by the cardiologist. It could be prescribed by the family provider or could have been punted to like a vascular clinic like where I was working. It can go to any of those. And when you send that fax, right, if it goes to the cardiologist and it's supposed to go to the family care provider, like it just kind of goes, goes nowhere, right, from there. So I think it's a really good idea to find out who prescribed it last. If the patient doesn't know who prescribed their blood thinner last, you can call their pharmacy. I call pharmacies all day long.   I have noticed in the last year, they are way easier to get a hold of, which has made my job a lot easier, working on the insurance portion. So reaching out to the pharmacy, finding out who that provider is and sending it to them, because they should be able to help with that. I thought that was a good shift in verbiage that you had of asking instead of like the cardiologist, because that's who you would assume was the one. But you said like so many times you guys would take care of them, and then they go back to family practitioner, and you guys would get the clearances, but you couldn't clear because you weren't overseeing. So just asking the patient.   who prescribed their medication for them last time. That way you can send the clearance to the correct provider. then- And they might not know. You know patients, right? They're like, I don't know, my mom's or else, I don't know who gave it to me. Somebody told me I need to be on this. But at least that could be another quick thing. And then also we were talking last night about-   ⁓ What are some other things that dentists can do when like writing scripts to help them get what I think like overarching theme of everything we discussed is one how to help dentists have less I think drag through pharmacy. ⁓ Because pharmacy can take a little while and so perfect we now know the difference between anti-quag and anti-platelet. We know which medications are probably safe. We know we can check the ADA guidelines so that we were not having to do as many clearances. We also know if they're on a medication to find out and we do need a clearance.   who we can go to for the fastest, easiest result. And now, in talking about prescriptions, you had some really interesting tips that you could share with them. Yeah, so with writing prescriptions, right, pharmacies are pharmacies. So I'm not gonna say good thing or bad thing. There are challenges working with pharmacies. I'm not gonna play that down at all. ⁓ If you're writing prescriptions and having issues and kickbacks from pharmacies, there's some interesting laws around ⁓ writing prescriptions. Say that you're trying to ⁓ prescribe   augmentin, you know, 875 BID, and you tell the patient, hey, I want you to take this twice a day for seven days, and then you put quantity of seven, because you're moving fast, right? You want it for seven days, quantity of seven. Quantity would actually be 14, right? It's not that big of a deal. Anybody with common sense would say if you're taking a pill for twice a day for seven days, you need 14 tablets. But LAHA doesn't allow pharmacists to make that kind of a change, unfortunately. They have to follow what you're saying there. So you're going to get a...   An annoying callback that says, you wrote for seven tablets. I know you need 14. Is that OK? Just delays things, right? So ⁓ I really like the two letters QS. That's Q isn't queen. S isn't Sam. Yeah. It stands for quantity sufficient. So you don't have to calculate the amount of any medication that you're doing. So for me, as a pharmacist, when I was taking care of patients, I hated calculating the amount of insulin they would need for an entire month. So I would say.   Mrs. Jones needs 15, I'd say 15 units ⁓ QD daily. ⁓ And then I say QS, quantity sufficient, ⁓ 90 day supply through refills. So the pharmacy can then go calculate how much insulin that they need. I don't have to even do that. So anytime you're prescribing anything, I like that QS personally. So that lets the pharmacy use ⁓ common sense, as I like to call it, instead of giving you a call. I think that's super helpful. I also thought of one thing too.   going back to blood thinners is when it's kind of like a real quick, like they're not gonna have you stop the blood thinner at all. like you're seeing if you can stop the blood thinner for a patient, there's some instances it's just not gonna happen. And that's whenever they've been, they've had a clot or a stroke or a heart attack within the last three months. Three months. Yeah, that's kind of like the.   Because so many people are like, they had a heart thing like six years ago. And so I think a lot of my dentists that I worked with were like, we got to stop the blood thinners. But it sounds like it's within three months. Yeah, well, I'm just the time. Like this is general broad strokes. What I'm just trying to say is when you want to expect a no real quick. Got it. Right. So because benefits of stopping a blood thinner within those first three months of an event is very, very risky versus the, you know, the benefit of reducing a little bit of blood coming out of the mouth. Right. Like that's not that bad.   when somebody's had a stroke or a heart attack or pulmonary embolism, a clot in the lung, like we can't replace the lung, heart or brain very easily. We can replace blood a lot better. We've got buckets of it at most hospitals have buckets of it, right? So I'm always kind of leaning towards I'd rather replace blood than tissue at all times. So that's kind of a quick no. If they've had one those events in the last three months, we are really, really gonna watch their brain instead of getting.   root canal, right? Like really worried about them. So you'll just say no. And they could the dentist still proceed with the procedure or would you recommend like a three month wait? Or is it provider specific way the pros and cons because sometimes you need to get that tooth out. Great question. think then it's going to come into clinical. That's that's when you send in the clearance, right? Like, and it's great to reach out to the provider who's managing it for you. But I think it's kind of good to know exactly when you get a quick no quick no is going to be less than three months.   ⁓ Or when it's going to be like a kind of a typical, yeah, no problem. If it's been no greater than six months, they're on the typical anticoagulants or alto eloquence. Nothing crazy is going on for them. You're only removing two teeth. This is very, very low risk. But again, I'd urge everybody to read the ADA guidelines. That way you feel more comfortable with it. I'm not as eloquent as they do. They do a real good job. So I don't want to take any of their credit. I think they do a real good job of simplifying that and making you feel confident with providing.   more timely care for patients. Which is amazing. And Jayce, one last thing. I don't remember what it was. You were talking about the DEA and like six month rule. yeah. Let's just quickly talk about that and then we'll wrap this because this is such a fascinating thing for me last night. Yeah. So when comes to prescribing controlled substances, most providers have to have a DEA license. OK. First of all, though, what's your take on dentist prescribing controlled substances? ⁓ I don't think, you know, I worked on the insurance side of things. Right. And I look at the requirements for the   as the authorizations, what a patient, the criteria a patient needs to hit in order to qualify for certain medications. A lot of times for those controlled substances, they have pretty significant issues going on, like fibromyalgia or cancer-related pain or end-of-life care versus we don't, in all my scanning thread, I don't have a ⁓ perfect picture memory. Sure. But I don't usually see oral.   pain in there. There is some post-operative pain that can be covered for those kind of medications but I really recommend to keep those lower and in fact in a lot of our criteria it recommends you know have they tried Tylenol first, they tried, have they filled NSAIDs or are they contraindicated with the patient. So really they should be last line for patients in my two cents but there's always going to be a caveat to the rule right? Of course. comes through that has oral cancer and you're taking   like that would make sense to me. Got it, so then back to the DEA. Yeah, okay. Okay, ready. So as a provider, you should be checking the, if you're doing controlled substances, you should be checking the prescription drug monitoring program, or sometimes called the PDMP, looking to see if patients are getting ⁓ controlled substances from another provider. So it's really just a check and balance to make sure that they're not going from provider to provider to getting too many narcotics and causing self harm or harm to others.   And so with checking that PDMP before prescribing, I think a lot of providers do that. A lot of softwares that I'm aware of, EMRs, electronic medical records, sometimes have links so that you can do that more quickly. However, I don't think it's as intuitive that they need to be checking that every six months in some states. And like here in Nevada, you're supposed to be checking it every six months, not for a patient, but for your actual DEA registration to see if anybody else is prescribing underneath you. Because if you don't check that every six months, you could get in some serious trouble with...   not only DEA, but even more the Board of Pharmacy and your state. Now, I don't know all 50 states, so I check with your state to see if you need to be checking that every six months, but set an alarm just to check that real quickly, keep your nose clean. ⁓ I've had providers, I've had to remind to do that. And if somebody was using your account, prescribing narcotics, you'd never know unless you went and checked that PDMP.   Yeah, I remember last night you were like, and if that was you, I would not want to be you. The Board of Pharmacy is going to be real excited to find you. So that was something where I was like, got it. So, and we all know I'm big on let's make it easy. And Jason, I love that you love this so much and you just brought so much value today. And like also for me, it's just fun to podcast. fun. Yeah. But I got a nerd out on my world a little bit. Bring it into yours. I work with dentists or at least you know, when I was working in Vascular Clinic all day long. Great questions that would come through. Yeah.   So I think for all of us, as a recap on this is number one, I think setting yourself ⁓ some cadences. So maybe every quarter we check our ADA guidelines and we check our, what is it, PDMP. PDMP. so each state, so they call it Prescription Drug Monitoring Program. We need that. Yeah, but there are different acronyms in different states, though. That's just what it's called in Nevada. I forget what it is in California, but you can check your state's prescription monitoring program, make sure that opioids aren't being prescribed under your name. Got it. So we just set that as a cadence.   We know one to three teeth most likely if they're on a blood thinner is According to the 88 as of today is good to go You know things that are going to get a quick know are going to be within the last three months of the stroke the heart attack or the Clot I'm thinking like the pulmonary embolus. Yeah, that's what we're trying to prevent   Those are gonna be quick knows and then if we're prescribing, let's do QS. We've got quantity is sufficient so that we're not getting phone calls back on those medications that we are. And then on narcotics, just being a bit more cautious. Of course, this is provider specific and in no way, or form did Jason come on here to tell you you are the clinical expert.   Jason's the clinical expert on medications. And if you guys ever have questions, I know Jason, you geek out and you want to talk to people so that anyone wants to chat shop. Be sure to reach out and we'll be able to connect you in. we've even talked about possibly, so let me know listeners. You can email in Hello@TheDentalATeam.com of ask a pharmacist anything. I talked to Jason. I was like,   We'll just have them like send in questions and maybe get you back on the podcast or we do a webinar. But any last thoughts, Jace, you've got of pharmacy and dentistry as we as we wrap up today? No, I think that's pretty much it. So check the ADA guidelines. I think it's really good to have cross communication between professions. Right. If you're working with the pharmacy, CVS, Walgreens or something like that or Walmart, I know that it can be challenging. Right. They're under different pressures. You're under different pressure. So I think ⁓ just coming in with an understanding, not being angry at each other.   you know what mean, is super beneficial and working together. When it comes to it, every dentist that I've talked to is actually worried about their patient. Every pharmacist that I've worked with is really worried about the patient as well. So we're trying to accomplish the same thing, but we have different rules and our hands are bound in different ways that annoy each other, right? Like I know Dr. Jones, want 14 tablets, but you said seven. And I know Common Sense says I should give them 14, but I've got to make that change.   knowing that their hands are tied by the law. They can't use as much common sense, which is aggravating. I mean, that's why I love what I gotta do here. I gotta just kind of help a lot more and use common sense and improve patient care. But those kinds of things I think are really beneficial as you work together and then not being so afraid of blood thinners, right? So I think those guidelines do a great job of giving you confidence and not worrying about the side effects. And there's a lot of things that you can do locally for bleeding.   You have a lot of control over that. I think that's pretty cool, the tools they have. Yeah. And at the end of the day, yes, you are the clinician. You are the one who is responsible for this. so obviously, chat, but I think collaborating, talking to other pharmacists, talking to them in your state, finding out what are the state laws, things like that I think can be really beneficial just to give you peace of mind and confidence. And again, dentistry, are maybe a bit more risk adverse because luckily we don't have patients dying That's great thing. Yeah, that's fantastic. I want my dentists to be risk adverse. I think so too. But Jason, I appreciate you being on the podcast today.   And for all of you listening, ⁓ more confidence, more clarity, more streamline to be able to serve and help our patients better. if we can help you in any way or you've got more questions, reach out Hello@TheDentalATeam.com. And as always, thanks for listening. I'll catch you next time on the Dental A Team podcast.  

This issue will review: 1.     Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial 2.     Impact of Oral Semaglutide on Kidney Outcomes in People with Type 2 Diabetes: Results from the SOUL Randomized Trial 3.     The effect of substituting water for artificially sweetened beverages on glycemic and weight measures in people with type 2 diabetes: The Study of Drinks with Artificial Sweeteners (SODAS), a randomized trial 4.     Effects of carbohydrate-restricted diets and macronutrient replacements on cardiovascular health and body composition in adults: a meta-analysis of randomized trials Trial Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

The American Diabetes Association's 2026 Standards of Care in Diabetes are here! Let's talk about what's changed and how to better care for our older adults living with diabetes. 2026 Standards of Care in Diabetes:  https://diabetesjournals.org/care/issue/49/Supplement_1 Tamara Ruggles, PharmD, BCGP, FASCP:  www.linkedin.com/in/tamara-ruggles-491882251 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES:  https://www.linkedin.com/in/diana-isaacs-pharmd-bcps-bcacp-bc-adm-cdces-45803426/  

In this month's podcast episode, The Standards, hosts Neil Skolnik, MD, and Sara Wettergreen, PharmD, BCACP, BC-ADM, explain the Standards of Care in Diabetes from the American Diabetes Association® in clear, plain terms. This conversation is designed to help you better understand the guidance that shapes diabetes and obesity care. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to "follow" Diabetes Day by Day!   Additional resources: Access the Standards of Care in Diabetes—2026 Access sections 1-3 of the Standards of Care in Overweight and Obesity Access Your Rights and Care Standards: A Guide for People with Type 2 Diabetes          

In this special series on Automated Insulin Delivery our host, Dr. Neil Skolnik will discuss with the benefits of Automated Insulin Delivery for people with Type 2 Diabetes. This special episode is supported by an independent educational grant from Insulet. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Davida Kruger, MSN, APN-BC,BC-ADM,  Henry Ford Health, Detroit, Michigan. Past Chair of the American Diabetes Associations Research Foundation, Past president, Health Care and Education of the American Diabetes Association. Ashlyn Smith, MMS, PA-C, DFAAPA, LSC, Distinguished Fellow of the American Academy of PAs, Certified Diabetes Prevention Program Lifestyle Coach, Founder of ELM Endocrinology & Lifestyle Medicine, PLLC., Past President of the American Society of Endocrine Physician Assistants, Adjunct faculty at Midwestern University, Selected references: Automated Insulin Delivery in Adults With Type 2 Diabetes A Nonrandomized Clinical Trial. JAMA Network Open. 2025;8(2):e2459348. A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.  N Engl J Med 2025;392:1801-12 Automated Insulin Pump in Type 2 Diabetes – Editorial - N Engl J Med 2025;392:1862-1863

I am thrilled to have Dr. Ken Berry joining me on the podcast for the third time today. He was with me before on episodes 111 and 139. Dr. Berry is a physician, best-selling author, and passionate health advocate with a no-nonsense approach to health and wellness. He has been practicing at the Berry Clinics since 2003 and is an active community member. He has written two books, Lies My Doctor Told Me and the recently published Kicking Ass After Fifty, in addition to various other resources, including Common Sense Labs Today. He also has a YouTube channel, serving over 2 million subscribers- one of my favorite go-to resources for my patients.  In our conversation today, we dive into the latest Lancet research on the impact of a diabetes diagnosis on life expectancy, along with insights from the American Diabetes Association regarding the costs of diabetes care. We discuss the need for proper diagnostic modalities to identify insulin resistance earlier and the labs Dr. Berry uses in his practice for identifying those at risk. We explore the recently recognized American Heart Association syndrome, CKM (Cardiovascular Kidney Metabolic Syndrome), and the role of GLP agonists, continuous glucose monitors, and glucometers. Dr. Berry also shares his views on plant-based diets, proper diets, and more.  IN THIS EPISODE YOU WILL LEARN: Why does metabolic health continue to deteriorate in most of the general population?  The staggering amount of disposable plastic used within the healthcare industry The importance of fasting insulin levels when diagnosing metabolic disease Why are blood tests essential for determining metabolic health? The benefits of glucometers and continuous glucose monitors for metabolic health How Dr. Berry's health improved after following a specific diet and measuring his lab results for a month How misinformation gets spread within the health and wellness industry Why are doctors not informing their patients about the absence of long-term studies and deluding them with false information? The long-term effects of Semaglutide on the body  How a proper diet can naturally lower lipid levels The limitations of the germ model for treating chronic diseases  Connect with Cynthia Thurlow Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Join other like-minded women in a supportive, nurturing community (The Midlife Pause/Cynthia Thurlow)  Cynthia's Menopause Gut Book is on presale now! Cynthia's Intermittent Fasting Transformation Book The Midlife Pause supplement line Connect with Dr. Ken Berry On ⁠YouTube⁠ ⁠Instagram⁠, ⁠Facebook⁠ ⁠Twitter⁠ Dr. Berry's books ⁠Lies My Doctor Told Me⁠  ⁠Kicking Ass After 50⁠    ⁠Common Sense Labs⁠  Dr. Berry's Private Community ⁠Phdhealth.community⁠ Medical News article Mentioned ⁠Here's What to Know About Cardiovascular-Kidney-Metabolic Syndrome, Newly Defined by the AHA ⁠  Previous Episodes Featuring Dr. Ken Berry ⁠Ep. 111 – Is The Keto Diet The Proper Human Diet? – with Dr. Ken Berry⁠ ⁠Ep. 139 – Hyperinsulinemia: What You Should Know About This National Health Crisis with Dr. Ken Berry

This issue will review: 1.     Evolocumab in Patients without a Previous Myocardial Infarction or Stroke 2.     SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria 3.     Continuous SGLT-2, GLIP-1RA and Frailty Progression in Older Adults with Type 2 Diabetes   4.     Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria 5.     Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial 6.     Listening to Hypoglycemia: Voice as a Biomarker for Detection of a Medical Emergency Using Machine Learning Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Can You Get the Benefits of a 5-Day Fast Without Starving?Click On My Website Below To Schedule A Free 15 Min Zoom Call:www.Over40FitnessHacks.comOver 40 Fitness Hacks SKOOL Group!Get Your Whoop4.0 Here!Ashley Bizzell - Registered Dietitianwww.L-NutraHealth.comProlon Fast Mimicking DietIn this episode, Brad Williams sits down with Ashley Bizzell, Registered Dietitian and Director of Clinical Nutrition and Global Training at L-Nutra Health, the company behind ProLon®, to dive deep into fasting, metabolic health, and the science behind the Fast Mimicking Diet (FMD).Ashley explains how she transitioned into clinical nutrition and now leads the medical arm of L-Nutra Health, which supports patients with metabolic conditions like prediabetes, obesity, high cholesterol, and type 2 diabetes through evidence-based nutrition therapy, telehealth physicians, and structured fasting programs. While ProLon is often viewed as a “fasting product,” Ashley reframes it as a nourishing technology designed to deliver the benefits of prolonged fasting—without the risks of complete food deprivation.Brad and Ashley break down what the Fast Mimicking Diet actually is: a precisely formulated 5-day program that provides real food—soups, bars, olives, teas, and healthy fats—while keeping the body in a fasting state. The conversation explores how the FMD supports autophagy, cellular cleanup, metabolic flexibility, and insulin sensitivity, while also offering muscle protection, a major concern for adults over 40.Brad shares his personal experience with water fasting, intermittent fasting, and ProLon, comparing fat loss, insulin control, ketosis depth, and autophagy. Ashley explains why ProLon is structured for five days, how autophagy ramps up around day three, and why day six refeeding with high-quality whole foods is just as critical as the fast itself.They also discuss:The role of fasting in reducing inflammation, improving lipid panels, liver health, insulin resistance, and even taste and smell sensitivityHow ProLon supports muscle preservation through targeted nutrients like glycerolWhy fasting is a positive, hormetic stress similar to exerciseThe importance of metabolic flexibility and why fasting gets easier over timeHow continuous glucose monitors (CGMs) can provide personalized insight into food responsesThe growing acceptance of fasting and food-as-medicine in mainstream healthcare, including L-Nutra's recent recognition by the American Diabetes Association for improvements in A1C and medication reductionAshley also highlights additional L-Nutra products, including vegan protein shakes and bars that support muscle without triggering aging pathways, as well as one-day fasting resets for beginners.If you're interested in online personal training or being a guest on my podcast, "Over 40 Fitness Hacks," you can reach me at brad@over40fitnesshacks.com or visit my website at:www.Over40FitnessHacks.comAdditionally, check out my Yelp reviews for my local business, Evolve Gym in Huntington Beach, at https://bit.ly/3GCKRzV

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss major diabetes technology updates alongside key technology-related changes in the 2026 American Diabetes Association Standards of Care. The conversation highlights how rapidly evolving devices and updated guidelines are converging to reduce treatment burden and expand access to advanced diabetes management tools. The discussion opens with updates from Dexcom, notably the launch of the Dexcom G7 15-day sensor, which incorporates an updated algorithm and is already integrating with Omnipod 5 and iLet systems, with Tandem integration expected soon. The hosts also address the announcement that the Dexcom G6 will be retired in July 2026, acknowledging the emotional and practical challenges this poses for patients who prefer the G6's connectivity and perceived accuracy. While the transition may be difficult for some, the longer wear time and algorithm improvements of the G7 are framed as an opportunity to reassess CGM options and prepare thoughtfully for change. Attention then shifts to Omnipod 5, with anticipation around a forthcoming software update planned for 2026. This update will introduce a lower glucose target of 100 mg/dL, down from 110 mg/dL, and significantly reduce automated-mode “kick-outs.” The hosts emphasize that minimizing time out of automated insulin delivery is critical for improving time in range and lowering patient burden, noting that excessive safety-driven exits can paradoxically worsen glycemic control. A substantial portion of the episode is devoted to technology-focused updates in the 2026 ADA Standards of Care, reflecting Bellini's perspective as a guideline committee member. Key changes include the removal of C-peptide and autoantibody requirements as barriers to insulin pump and automated insulin delivery (AID) access, reinforcing that insulin use, not diabetes type, should guide eligibility. The guidelines now include a Level A recommendation for AID use in type 2 diabetes, supported by recent clinical trial data and regulatory approvals. Additional updates expand support for CGM use during pregnancy beyond type 1 diabetes, reduce reliance on confirmatory fingerstick language, and strengthen recommendations for connected insulin pens for individuals on multiple daily injections when AID is not preferred or feasible. The episode concludes with discussion of expanded guidance on open-source AID systems, underscoring the importance of clinician understanding and patient support regardless of FDA approval status. Collectively, Isaacs and Bellini frame the 2026 updates as a decisive step toward earlier, broader, and more individualized use of diabetes technology across care settings. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. References: American Diabetes Association. The American Diabetes Association Releases “Standards of Care in Diabetes—2026” | American Diabetes Association. Diabetes.org. Published December 8, 2025. Accessed December 17, 2025. https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2026 American Diabetes Association Professional Practice Committee for Diabetes*. Summary of Revisions: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(1 Suppl 1):S6-S12. doi:10.2337/dc26-SREV Chapters 00:00:00 - Intro & Agenda: New Tech + 2026 ADA Standards 00:00:45 - Dexcom G7 15‑Day Sensor & G6 Retirement 00:04:40 - OmniPod Algorithm Update 00:09:27 - 2026 ADA Standards of Care 00:15:45 - Expanding Diabetes Tech Options 00:21:19 - Endorsement of Earlier AID and Open-Source AID Support

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, share early impressions of topline phase 3 results from the TRIUMPH-4 trial of retatrutide, a once-weekly triple agonist targeting GIP, GLP-1, and glucagon receptors.  Recorded from the ADCES Technology Conference, the conversation frames retatrutide as a potential next step beyond current GLP-1 and dual incretin options, while emphasizing that detailed trial data remain pending. TRIUMPH-4 was a phase 3 study enrolling patients with obesity and osteoarthritis. Topline data suggests participants receiving retatrutide 12 mg achieved a mean weight loss of 28.7% at 68 weeks. Among this population, the trial also reported a 75.8% reduction in WOMAC pain scores from baseline, with approximately 1 in 8 participants reporting complete pain freedom at week 68. Isaacs highlights how striking these figures are in light of the already high bar set by semaglutide and tirzepatide, noting that confirmation in phase 3 heightens anticipation for full publications and future readouts. The hosts connect these findings to evolving clinical priorities reflected in the American Diabetes Association's expanding attention to obesity-related comorbidities, including osteoarthritis, MASLD/MASH, sleep apnea, and kidney disease. They note the broader retatrutide phase 3 program includes studies in type 2 diabetes, moderate-to-severe obstructive sleep apnea, chronic low back pain, MASLD/MASH, and planned cardiovascular and renal outcomes trials. Isaacs underscores the ongoing question of whether benefits across these conditions will be primarily molecule-specific or largely driven by the magnitude of weight loss, particularly given the inclusion of glucagon receptor activity. Safety is discussed cautiously, given the limited nature of top-line disclosures. The hosts note that discontinuation due to adverse events appeared higher with retatrutide than placebo, and they emphasize the need for full reporting on gastrointestinal tolerability and other adverse events. Bellini also points to an intriguing subgroup signal suggesting lower discontinuation rates among participants with higher baseline BMI, while acknowledging this could reflect chance in a modestly sized trial population. Overall, Isaacs and Bellini characterize retatrutide's TRIUMPH-4 update as an important milestone, while stressing that interpretation should remain measured until complete efficacy and safety data are available. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. References: Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. December 11, 2025. Accessed December 11, 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average American Diabetes Association. The American Diabetes Association Launches a New Obesity Division | ADA. diabetes.org. Published June 21, 2024. Accessed December 16, 2025. https://diabetes.org/newsroom/press-releases/american-diabetes-association-launches-new-obesity-division

In this special series on Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated steatohepatitis (MASH) our host, Dr. Neil Skolnik will discuss Epidemiology, Importance, Screening, Diagnosis and Treatment of MASH. This special episode is supported by an independent educational grant from Boehringer Ingelheim. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Alina M. Allen, M.D. Associate Professor of Medicine at Mayo Clinic in Rochester, Minnesota, where she serves as the Director of Hepatology and Director of the MASLD Clinic. Selected references: Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care 2025;48(7):1057–1082

Welcome to Ozempic Weightloss Unlocked, the podcast that unpacks how this medication is reshaping health, lifestyle, and the future of weight management.Ozempic is a brand name for semaglutide, a medication originally approved to treat type two diabetes. It mimics a gut hormone that helps the pancreas release insulin, lowers blood sugar, slows stomach emptying, and signals the brain to feel full sooner. The result for many people is significant weight loss, which is why a higher dose of the same drug is sold separately for obesity under the name Wegovy, according to the United States Food and Drug Administration and the National Institutes of Health.Because of this dual effect on blood sugar and appetite, Ozempic has become a cultural phenomenon. Listeners hear about it from celebrities, social media, and even coworkers, but medical experts keep stressing one key point. These are prescription drugs meant for people with type two diabetes or with obesity and related health risks, not quick fixes for casual weight loss. Major medical groups such as the American Diabetes Association and the Obesity Society are pushing to protect access for patients who truly need them.Recently, attention has shifted to what happens beyond the number on the scale. Some people lose not only fat but also muscle, which can affect strength, mobility, and metabolism. Researchers at Karolinska Institutet and Stockholm University, writing in the journal Cell, report a new tablet treatment that increases fat burning and improves blood sugar while preserving muscle mass, and it works very differently from Ozempic. Instead of acting on appetite in the brain, it targets skeletal muscle directly, and early trials suggest it may be used alone or even combined with a drug like Ozempic in the future.At the same time, the competition in obesity medicine is heating up. Eli Lilly has developed a so called triple hormone drug called retatrutide that activates three receptors instead of one. Eli Lilly and coverage from outlets like ABC News report that in a large trial of people with obesity and knee osteoarthritis, participants on the highest dose lost nearly twenty nine percent of their body weight on average and saw a big drop in knee pain. While retatrutide is still in clinical trials and not yet approved, it shows how the field is racing to go beyond the results seen with Ozempic alone.For listeners, this rapid progress brings both excitement and responsibility. These medications can improve blood sugar, reduce cardiovascular risk, and help treat diseases linked to excess weight, but they can also cause nausea, vomiting, diarrhea, and in some cases gallbladder or pancreatic issues. Long term use may require monitoring of muscle mass, nutrition, and mental health. Physicians are now talking more about pairing these drugs with resistance training, adequate protein, and psychological support so that weight loss does not come at the cost of strength or well being.Ozempic has also raised bigger questions. Who should get access when supplies are limited. How will insurance handle long term therapy for what is often a chronic condition. And what happens if a person stops the medication and the hunger comes back. Early data suggest that for many, maintaining results may require ongoing treatment, much like blood pressure medicine.On Ozempic Weightloss Unlocked, we will keep tracking all of this. From new trials and pill based options, to combination therapies, insurance changes, and real world stories of how life looks on and off these medications, our goal is to give you clear, balanced information so you can have better conversations with your own health care team.Thank you for tuning in, and remember to subscribe so you never miss an update on the evolving world of Ozempic and weight loss science.This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In this special series on Automated Insulin Delivery our host, Dr. Neil Skolnik will discuss with Davida Kruger the benefits of Automated Insulin Delivery for people with Type 2 Diabetes. This special episode is supported by an independent educational grant from Insulet. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Davida Kruger, MSN, APN-BC,BC-ADM,  Henry Ford Health, Detroit, Michigan. Past Chair of the American Diabetes Associations Research Foundation, Past president, Health Care and Education of the American Diabetes Association. Selected references: Automated Insulin Delivery in Adults With Type 2 Diabetes A Nonrandomized Clinical Trial. JAMA Network Open 2025;8(2):e2459348. A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes. N Engl J Med 2025;392:1801-12 Automated Insulin Pump in Type 2 Diabetes – Editorial. N Engl J Med 2025;392:1862-1863

First shots fired in war against ultra-processed foods; What the big reveal of Trump's MRI really shows; Is cruelty to horses really necessary to make estrogen? Early smartphone use linked to mental harms in kids; Nutritionist sues American Diabetes Association for forcing her to promote unhealthy artificial sweeteners; Halle Berry dings California Governor Newsom for vetoing menopause awareness bill.

Chuck discusses Gray Line Tennessee's initiatives supporting education, veterans, and diabetes awareness, while explaining the American Diabetes Association's mission and its impact in Tennessee. Chuck serves as the 2025 State of Diabetes Chair for the American Diabetes Association, and shares why and how he personally got involved in supporting the organization that focuses on preventing and curing diabetes and improving the lives of all people affected by diabetes. Chuck discusses their work in funding research, driving advocacy, providing education and building connections and networks of support. The conversation concludes with details about Camp Sugar Falls, a diabetes camp for children, and various association events focused on fundraising, education, and community involvement.SummaryGray Line Tennessee's Community Support Initiatives - Chuck Abbott, President and CEO of Gray Line Tennessee discusses the company's community-focused values and its partnership with the American Diabetes Association. Chuck explained that Gray Line Tennessee, a 52-year-old sightseeing and motor coach company with over 320 employees and 250 vehicles, prioritizes employee health and education, particularly regarding diabetes awareness. The company's involvement with the American Diabetes Association aligns with its mission to educate employees about maintaining a healthy, balanced life, especially given the sedentary nature of many of their roles.Chuck also discusses the company's involvement with PENCIL, an organization supporting Metro Nashville Public Schools, and Operation Stan Down Tennessee, which helps veterans transition to civilian life. He emphasizes the importance of giving back to the community and supporting education and veterans, noting that employees are encouraged to promote their preferred charities within the organization, as well..American Diabetes Association Overview - Chuck provides an overview of the American Diabetes Association's mission to prevent and cure diabetes, improve lives of those affected, and advocate for policy changes. He highlights that the organization, celebrating 85 years, has over 500,000 volunteers and funds critical research, including at Vanderbilt University Medical Center in Nashville. In Tennessee, diabetes affects over 820,000 people, with significant healthcare and productivity impacts, and Chuck shares his personal connection to the cause through his granddaughter's diagnosis.Understanding Diabetes: Types and Treatments - Chuck and Jeremy discuss the personal impact of diabetes, with Chuck explaining the differences between type 1 and type 2 diabetes. Chuck describes type 1 as an autoimmune condition where the immune system destroys insulin-producing cells, while type 2 involves the body's inability to effectively use insulin. They discuss advancements in technology and research for diabetes treatment, including potential future developments like an artificial pancreas. Both express optimism about ongoing research and the hope for a cure.Diabetes Camp Volunteer Experience - Chuck shares his experience volunteering at Camp Sugar Falls, a diabetes camp for children aged 6 to 15, where he first became involved when his granddaughter, who was diagnosed with Type 1 in 2016, was too young to attend but could go with a family member. Chuck, who was the counselor in charge of 6- and 7-year-old campers during his first year, describes the camp as a welcoming environment where children learn to manage their diabetes while forming lasting friendships. He highlights the involvement of medical professionals from Vanderbilt and counselors from Belmont School of Pharmacy, and notes that the camp, founded in 1982, provides not only diabetes management education but also a supportive community for families dealing with the condition.American Diabetes Association Initiatives - Chuck discusses various events and initiatives organized by the American Diabetes Association, including the Step Out Walk, State of Diabetes, and Camp Sugar Falls, highlighting their focus on fundraising, education, and awareness. He emphasizes the importance of community involvement and volunteering, noting that the association efficiently manages funds to support research and aid individuals with both type 1 and type 2 diabetes.Resources for Diabetes AwarenessVisit diabetes.org to learn more about the American Diabetes Association and to access resources, information and upcoming events.Visit graylinetn.com to learn more about Gray Line Tennessee and their community initiatives and focus on customer service.

This issue will review: 1.     Screening Natriuretic Peptide Levels Predict Heart Failure and Mortality in Individuals with Type 1 and Type 2 Diabetes without Known Heart Failure 2.     The Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications In Patients with Type 2 Diabetes 3.     Continuous Glucose Monitoring Frequency and Glycemic Control in People With Type 2 Diabetes – JAMA Network Open  4.     An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program A Randomized Clinical Trial 5.     Two-tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: A multicenter cross-sectional study 6.     Change in urine albumin-to-creatinine ratio and clinical outcomes in patients with chronic kidney disease and type 2 diabetes   Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Researchers from Virginia Tech have discovered that ultra-processed meats and beverages are the worst for brain health. Individuals who consumed one or more extra servings of either of these foods showed a significantly increased risk of developing cognitive impairments, including those associated with forms of dementia such as Alzheimer's Disease. A recent article from Children's Health Defense shared new research ranking which junk foods are most harmful to the brain — and it's not just about kids' waistlines or sugar highs. It's about how what we eat can shape how we think, learn, and even feel. Let's dig into what this new research is saying, and more importantly, what it means for our families. How Junk Food Impacts the Brain These studies found that foods loaded with refined sugar, unhealthy fats, and artificial ingredients don't just harm the body — they change how the brain functions. Think of it like this: the brain runs on clear signals, kind of like a radio station. When it's getting clean fuel — whole foods, real nutrients — that signal is clear. But when it's constantly fed ultra-processed foods, it's like turning up the static. The brain starts to lose focus, memory gets fuzzy, and mood and motivation can shift. Ultra-Processed Foods (UPFs) are now known to include obesity, type 2 diabetes, cardiovascular diseases, anxiety, depression, and an increase in all-cause mortality. In fact, according to a study published in Diabetes Care, a journal of the American Diabetes Association, up to 220,000 young Americans under age 20 are likely to have Type 2 diabetes by 2060 — a 673% increase from 2017 levels. One of the studies found that people who ate a lot of processed meats, fried snacks, and sugary drinks had measurable changes in the areas of the brain that control memory and emotion. Another study showed that even short-term diets high in sugar and fat can rewire how the brain's “reward center” works — making people crave those same foods even more. A study of nearly 124,000 people found that drinking just one daily serving of artificially sweetened drinks increased the risk of a liver disease known as nonalcoholic fatty liver disease or metabolic dysfunction. That means the more we eat these foods, the more our brains want them, creating a loop that's hard to break. Why Kids Are Especially Affected Recent research has shed light on a startling concern—more than 300 chemicals have been detected in babies' cord blood and placenta at birth. This discovery highlights the fact that exposure to harmful chemicals begins much earlier than we previously thought. From conception through pregnancy, toxins can pass from the mother to the fetus, raising concerns about their potential long-term effects on child development and health. Children's brains are still developing, which makes them much more sensitive to these kinds of foods. When a growing brain is constantly exposed to sugary, processed foods, it can interfere with how nerve connections form. Some of the research cited by Children's Health Defense found that kids and teens who eat a lot of junk food have more trouble with memory and learning, and can experience more mood swings or attention issues. Part of that is because junk foods crowd out the nutrients that developing brains need — like omega-3s, zinc, and iron. And part of it is chemical: those processed ingredients can actually change the way the brain's reward systems respond, which makes healthy foods less appealing over time... Click Here or Click the link below for more details! https://naturallyrecoveringautism.com/233

With November being National Diabetes Awareness Month, join us for a special episode with the CEO of the ADA, Charles Henderson! We'll have a great conversation about the growing impact of diabetes in America, how the ADA is leading the fight for awareness and access!

Emily welcomes Rachel Proper from Caterpillar Safety Services, for a special episode in recognition of National Diabetes Month. Rachel shares a deeply personal and powerful story about her 13-year-old daughter's recent diagnosis with Type 1 diabetes. She explains how her own family history with the disease allowed her to recognize the subtle but serious symptoms, leading to an early diagnosis that prevented a life-threatening situation. This episode is a crucial listen for everyone, as it details the specific signs of both high and low blood sugar. Rachel provides a firsthand account of the symptoms her daughter experienced - from unintentional weight loss and increased hunger to excessive thirst and urination. The conversation also explores the importance of fostering a "culture of care" in the workplace, where employees feel psychologically safe and supported, whether they choose to disclose a health condition or not. Rachel's story is a poignant reminder of how awareness and early detection can save lives. Main Themes: The signs and symptoms of high blood sugar (hyperglycemia), such as weight loss, excessive thirst, and frequent urination. The signs and symptoms of low blood sugar (hypoglycemia), such as shakiness, paleness, confusion, and fatigue. The role of family history and personal experience in recognizing health warning signs. The seriousness of diabetic ketoacidosis (DKA), a life-threatening complication of diabetes. The importance of creating a workplace with strong psychological safety. How a "culture of care" encourages openness and allows coworkers and leaders to provide appropriate support. Toolbox Talk Discussion Questions: In this episode, Rachel shares about how her daughter was diagnosed with Type 1 diabetes. Thanks to her awareness of the disease, Rachel and her daughter were able to seek medical attention and get her treatment before there were any serious complications. How can we relate this kind of awareness and quick thinking to safety on site? What do you think are some of the benefits of sharing important medical information with coworkers?  Does anyone have a story they would like to share about recognizing the symptoms of a disease or condition? Key Takeaways: "Type 1 diabetes is an autoimmune disease. Our body attacks insulin-producing cells in the pancreas."   "Early detection of diabetes can prevent severe complications, including death."   "A culture of care with strong psychological safety encourages openness about health conditions."   "Employees don't have to disclose they're diabetic, but sharing can help coworkers respond appropriately."   "Awareness of diabetes symptoms can help catch the disease early and save lives." Links: National Stone, Sand & Gravel Association website Take Control: Prevent Serious Injuries and Fatalities: https://www.nssga.org/industry-priorities/health-safety/take-control-prevent-serious-injuries-and-fatalities Rachel Proper: https://www.linkedin.com/in/rachelproper/ American Diabetes Association: https://diabetes.org/

This issue will review: 1.     Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis  - Diabetes Care 2.     Orforglipron, an Oral Small-Molecule GLP-1Receptor Agonist, in Early Type 2 Diabetes – NEJM 3.     Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment – NEJM 4.     Dementia Risk in People With Type 1 Diabetes and Associated Risk Factors – Diabetes Care 5.     Impact of baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and CKD – Diabetes Care 6.     Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity -  NEJM    Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

I am thrilled to have Gary Taubes back on the show today. (He was with me before on episode 137. Gary is an investigative science and health journalist whose work has been pivotal in catalyzing the low-carb keto movement. He has written many books, including his most recent, Rethinking Diabetes, and his articles are in many of the best anthologies. He has also received many science awards. Today's discussion is particularly significant, given the recent report from the American Diabetes Association revealing that the annual cost of diabetes in the United States reached a staggering $412.9 billion in 2022, with individuals diagnosed with diabetes now representing one in every four dollars spent on healthcare.  In our discussion today, we dive into the history of diabetes, pertinent statistics, the prevailing standard of care, and the transformative influence of insulin on diabetes management and reactive hypoglycemia. Gary provides insights into his reactions to GLP ones, the integration of medical and nutrition science into the medical field, and the influence of organizations such as the American Diabetes Association, AHA, USDA, and NIH. Our discussion also extends to the effects of pharmaceuticals, the shortcomings in our approach to diabetes management and existing models, and the challenge the low-carb community faces. Stay tuned for today's eye-opening conversation, where we shed light on the complexities surrounding diabetes care, explaining how simple lifestyle changes can tremendously improve quality of life. IN THIS EPISODE YOU WILL LEARN: Rethinking Diabetes is a groundbreaking exploration of diabetes diagnosis, management, and treatment Gary discusses the evolution of evidence-based medicine Why the traditional medical approach to treating diabetes is inadequate How the guidelines of the American Diabetes Association were based on outdated assumptions  How medical treatments compare with lifestyle changes for managing diabetes Controversies surrounding how the pharmaceutical industry has influenced the way medical associations have shaped their diabetes management policies How medical guidelines and dietary advice have evolved What constitutes a healthy diet? How patients often have trouble following diet recommendations, despite their best intentions Is obesity a hormonal disorder or caused by overeating?  Connect with Cynthia Thurlow Follow on X, ⁠Instagram⁠ & ⁠LinkedIn⁠ Check out Cynthia's ⁠website⁠ Submit your questions to support@cynthiathurlow.com Connect with Gary Taubes On his ⁠website⁠ X ⁠Facebook⁠ Previous Episode Mentioned ⁠Ep. 137 – High Blood Sugar Levels And Its Long-Term Damage with Gary Taubes⁠ Book Mentioned: Rethinking Diabetes: What Science Reveals About Diet, Insulin, and Successful Treatments is available from most bookstores or on ⁠Amazon⁠.

In this episode of Diabetes Day by Day, Drs. Neil Skolnik and Sara Wettergreen talk with Aaron Sutton, LCSW, BCD, CAADC, and Casey Coffman about decision fatigue—what it means and ways to cope, especially as the holiday season approaches. Living with diabetes means making countless decisions every day—from meal choices to medication timing. Over time, this can lead to decision fatigue, impacting both your mental health and diabetes management. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Aaron Sutton, LCSW, BCD, CAADC, Director of the Sutton Institute for Psychotherapy Casey Coffman, American Diabetes Association® volunteer and a person living with type 1 diabetes Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to "follow" Diabetes Day by Day!

See omnystudio.com/listener for privacy information.

In this special series on Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated steatohepatitis (MASH) our host, Dr. Neil Skolnik will discuss Epidemiology, Importance, Screening and treatment of MASH. This special episode is supported by an independent educational grant from Boehringer Ingelheim. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Jay Shubrook, D.O., Professor and Diabetologist in the Department of Clinical Sciences and Community Health At Touro University California College of Osteopathic Medicine Selected references: Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care 2025;48(7):1057–1082  

This issue will review: 1.     Once-weekly Ultra-processed Foods and Diet Quality in Association With Long-term Weight Change and Progression to Type 2 Diabetes Among Individuals With a History of Gestational Diabetes Mellitus—A Prospective Study 2.     Plant-Based Dietary Patterns Associated With Reduced Risk of All-Cause Mortality in Diabetes Subgroups 3.     Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes- NEJM   4.     Risk of Phimosis Associated With SGLT2i Versus GLP-1RA: A Danish Cohort Study 5.     GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Esse tópico foi abordado na revisão 38 do Guia TdC. Para saber mais, acesse: https://www.tadeclinicagem.com.br/guia/461/diabetes-mellitus-tipo-2-atualizacao-da-american-diabetes-association-de-2025/

In this episode, representatives from the American Diabetes Association (ADA), Phil, Billy Barry, and Craig Jackson, discuss the upcoming Step Out Walk event happening on Saturday at Grand Park in Westfield, Indiana. They highlight the ADA's mission to cure, prevent, and manage diabetes, touching on the growth of diabetes cases and the importance of community awareness. The representatives also share what attendees can expect at the event, including various activities and educational opportunities. Additionally, they hint at a competitive challenge from Pittsburgh and mention future plans for the ADA, including the State of Diabetes event in November. The goal is to rally more community involvement and fundraising to support diabetes research and management.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome back to Ozempic Weightloss Unlocked, the podcast dedicated to bringing you the latest news, updates, and insights on Ozempic and its impact on weight, health, and lifestyle.Today, we start with the basics: Ozempic is a medication based on semaglutide, and it is part of a class of drugs called GLP-1 receptor agonists. These drugs work by mimicking a hormone in your gut that helps regulate blood sugar and appetite. According to Purdue University, after a meal, the body naturally releases GLP-1, which helps stimulate insulin production and signals the brain to feel full. Ozempic uses a modified version of this hormone, which not only lowers blood sugar but also reduces appetite, leading to significant weight loss. Clinical studies suggest people can lose between five and twelve percent of their body weight, while also seeing improvements in blood sugar and cardiovascular health.Ozempic is recommended as the first injectable therapy for diabetes by the American Diabetes Association, but most of its headline-grabbing popularity now comes from its off-label use for weight loss. Over fifteen million adults in the United States now use medications like Ozempic, Wegovy, or similar GLP-1-based drugs. The Wall Street Journal reports that this number has been climbing steadily each year.But as more people turn to Ozempic, new challenges and concerns are emerging. The most common side effects are nausea and digestive issues, which can be so severe that up to forty percent of people stop using the drug within the first month, according to Tufts University researchers. Even for those who tolerate Ozempic, there are drawbacks. Experts at Purdue University caution that weight often returns when the drug is discontinued, meaning it is not a permanent fix. Other concerns are rising as well. Mass General Brigham recently published research in JAMA Ophthalmology that links semaglutide to a greater risk of non-arteritic anterior ischemic optic neuropathy, a condition that can cause sudden, permanent blindness. People with diabetes taking semaglutide were over four times more likely to develop this disorder than those who did not.At the same time, there is a lot of online buzz around microdosing, or taking very small amounts of GLP-1 drugs for longevity or anti-aging. The Washington Post and The Independent have both reported that leading experts see no solid scientific evidence that microdosing these drugs provides any benefit or is even safe. Companies marketing microdosing protocols are ahead of the actual science.Researchers at Tufts are now developing new medications that target even more hormone receptors, hoping to be more effective, easier to take, and come with fewer side effects. Their most recent breakthrough aims for a four-in-one drug that tackles multiple hormones tied to metabolism and appetite, with the goal of delivering even greater and longer-lasting weight loss. The hope is that future drugs could treat obesity and simultaneously reduce risks for over one hundred eighty diseases linked to excess weight, including diabetes, cancer, and heart disease.Meanwhile, there are also efforts to stimulate the body's own GLP-1 production naturally, possibly through dietary fibers or future supplements. Purdue researchers believe this could help people maintain weight loss after coming off Ozempic, without the harsh side effects of injections, though results so far show milder weight control than with the actual drug.To sum up, Ozempic has opened a new chapter in metabolic medicine, but there are still risks, unanswered questions, and an ever-changing landscape as science races forward. We will be here to keep you informed with the latest evidence and expert insights.Thank you for tuning in to Ozempic Weightloss Unlocked. If you found this episode helpful, please subscribe so you do not miss our future updates and expert interviews. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review:   1.     Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity  - NEJM   2.     Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3)– Lancet Diabetes Endocrinology    3.     Nutritional priorities to support GLP-1 therapy for Obesity – A Joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society - American Journal of Clinical Nutrition 4.     Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events – Diab Care 5.     Tirzepatide as Compared with Semaglutide for the Treatment of Obesity – NEJM For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Celebrate the American Diabetes Association®'s (ADA) 85th anniversary with Drs. Neil Skolnik and Sara Wettergreen, joined by Dr. Marlon Pragnell, Charlene Wallace, and Stacey Krawczyk. Together, they'll reflect on the ADA's legacy of groundbreaking research and how it continues to shape the programs and resources available today. The conversation will also highlight practical tools—from nutrition guidance to the National Diabetes Prevention Program—to support you and your loved ones in managing or preventing diabetes. Because it all matters. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Marlon Pragnell, PhD, Vice President of Research and Science at the ADA Charlene Wallace, MBA, Vice President of Diabetes Prevention at the ADA Stacey Krawczyk, MS, RD, Director of Nutrition and Wellness at the ADA Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to “follow” Diabetes Day by Day!   Additional resources: Research Impact   Learn More About the National Diabetes Prevention Program    Eating for Diabetes Management   Diabetes Food Hub   More on the ADA's 85th Anniversary

In this special episode on Treatment of Hypercortisolism in Uncontrolled Diabetes our host, Dr. Neil Skolnik, will discuss a case based approach to uncontrolled diabetes addressing new evidence showing the surprising prevalence of Hypercortisolism in people with uncontrolled Type 2 Diabetes, and the effect of treatment.  This special episode is supported by an independent educational grant from Corcept. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John Buse, MD – The Verne S. Caviness Distinguished Professor and director of the Diabetes Center at the University of North Carolina at Chapel Hill School of Medicine, a past president of medicine & science at the American Diabetes Association (ADA), and recipient of the ADA Outstanding Achievement in Clinical Diabetes Research Award John Anderson, MD - Practices internal medicine and diabetes at the Frist Clinic in Nashville Tennessee. Servied as a Past President of the 38-member multi-specialty clinic, and has served leadership roles at Centennial Medical Center, a 670 bed HCA tertiary care referral hospital. He has served as Chair of the Department of Medicine for two separate terms. Served two separate terms on the National Board of Directors for the American Diabetes Association, and in 2013 he received the Banting Medal for service as President of Medicine and Science for the ADA.   Reference:   Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care dc242841 https://doi.org/10.2337/dc24-2841   Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment. Diabetes Care June 2025  

  From Culture to Kitchen, A Healthy Plate My interview with Lorena Drago       In this episode, we cover: Chef Robert and Lorena Drago, a registered dietitian specializing in diabetes management and multicultural nutrition, discussed the importance of accurate dietary information and cultural considerations in diabetes care. They explored common myths about diabetes in Hispanic communities and shared insights about nutritious foods from Latin American cuisine, including beans, legumes, and various fruits and vegetables. We ended the conversation with Lorena's practical advice for managing blood glucose levels while enjoying traditional foods, along with tips for healthy grocery shopping on a budget, and she offered free webinars for further education. FREE OFFER I am offering a short course for free. This is the application: https://forms.gle/QFPffvJYDwUwdamv6 ______________________________________________________________ Nutrition and Cultural Diversity Journey Lorena shared her journey into the field of nutrition, motivated by her curiosity about the relationship between food and health, particularly how food affects diabetes management and connects with different cultures. She recounted an anecdote about being confused by the Spanish word for "orange" in a commercial, which led her to discover the cultural diversity within the Hispanic community, especially within Colombia's different regions. Chef acknowledged Lorena's experience and background, setting the stage for the main discussion. Hispanic Diabetes Diet Myths Debunked Lorena discussed common myths about diabetes in the Hispanic community, emphasizing that there is no single Hispanic diet and that dietary choices can be modified to manage diabetes. She clarified that all fruits contain carbohydrates, and blood glucose response depends on the type and quantity consumed, not just the sweetness. Chef Robert agreed and expressed frustration with misleading nutrition information online, advocating for consulting certified dietitians for accurate guidance. Lorena also noted that diabetes-friendly foods vary by cuisine within the Hispanic community. Hispanic Cuisines and Bean Benefits Lorena discussed the diverse Hispanic cuisines in the United States, focusing on Mexico as the largest subgroup. She highlighted the nutritional benefits of beans and legumes, emphasizing their protein, fiber, and mineral content. Lorena advised patients to consume more beans and legumes, noting their affordability and convenience, even suggesting canned beans as a quick option. Avocado's Journey to Trendy Superfood Lorena discussed the evolution of avocado from a lesser-known food among Hispanics to its current popularity as a trendy "It" food, noting its health benefits and the shift in perceptions about dietary fats. She also highlighted other nutritious foods from Latin American cuisine, including chia seeds, pumpkin seeds, quinoa, corn, chilies, and nopal cactus pads, emphasizing their health benefits and cultural significance. Chef Robert listened and engaged with comments, expressing interest in some of the foods mentioned. Blood Glucose Management Strategies Lorena shared her step-by-step approach to helping clients manage their blood glucose levels while enjoying traditional foods. She begins by assessing how clients monitor their glucose and gathers detailed information about their diet. Lorena then recommends paired testing for 2-3 days to track blood glucose responses to meals. Finally, she provides personalized recommendations aligned with American Diabetes Association guidelines, focusing on maintaining target blood glucose levels while incorporating traditional foods. Healthy Eating Strategies and Recipes Lorena discussed strategies for healthy eating, focusing on nutrient-dense options and carbohydrate management. She suggested making a French toast alternative with fruits, nuts, and a sweetener like date paste, which has a lower glycemic response than sugar or sugar-free syrup. Lorena emphasized the importance of tracking carbohydrate intake and using tools like CGM values to adjust meals accordingly. She encouraged trying the French toast recipe three times a week and enjoying sweetbreads about twice a week. Budget-Friendly Healthy Grocery Tips Lorena shared tips for healthy grocery shopping on a budget, emphasizing the importance of buying in-season produce and using frozen foods, which can be more cost-effective and just as nutritious as fresh options. She advised using AI for meal planning, shopping during senior discounts, utilizing coupons, and incorporating soy foods like tofu for protein. Chef agreed and highlighted the benefits of frozen foods, noting that many people overlook them due to misconceptions about freshness. Diabetes Management and Professional Guidance Chef and Lorena discussed the importance of clear communication and professional guidance for individuals managing diabetes, emphasizing the need for consulting healthcare professionals and diabetes educators to separate myths from facts. Lorena expressed joy in helping people gain the knowledge and skills to manage their condition effectively, leading to improved health outcomes and reduced need for frequent visits. She shared her social media platforms in both English and Spanish as the best ways for listeners to connect with her for further support. Diabetes Management Webinar Series Lorena Drago, a diabetes management expert, offered three free webinars on managing post-meal blood glucose levels, which she will contact participants about directly. Chef interviewed Lorena about diabetes management and concluded with a rapid-fire Q&A game. Chef mentioned that the podcast episode would be available in about a week, after a brief delay due to a family celebration of their new grandchild. How can our listeners connect with you? Website:www.lorenadrago.com Instagram: https://www.instagram.com/lorenadragomsrd          TikTok URL: https://www.tiktok.com/@lorenadiabetesnutrition Facebook SPANISH URL: https://www.facebook.com/lorenadragoexpertaendiabetes/ Facebook Group URL: https://www.facebook.com/Diabetesandnutritioneducation/ Twitter(X) URL: https://twitter.com/lorenadrago  LinkedIn URL:https://www.linkedin.com/in/lorenadrago/  Instagram SPANISH URL: https://www.instagram.com/diabetesandnutritioneducation/

An episode from The Holistic Navigator. This is not to diagnosis or treat any disease/illness. Consult your physician before taking supplements or medications OR before you stop taking medications. This is for entertainment/informational purposes only! Just as a refresher, diabetes is a disease that can cause blood glucose to stay in the bloodstream for prolonged periods. Our bodies secrete a hormone called insulin from our pancreas, which helps glucose be used for energy. When diabetes comes into play, our bodies don't use insulin correctly resulting in increased blood glucose levels in the bloodstream. This can lead to cardiovascular complications, glaucoma, nerve damage and even limb amputation. It's serious stuff that affects nearly half of the American adult population according to the American Diabetes Association. On this week's episode we want to address a few of the consistent questions we've been getting about this issue. There are measures that can be taken early on to help limit your possibility of developing diabetes, mainly stemming from a diet, nutrition, and supplementation perspective. Ed talks about why American diagnoses of diabetes are increasing, the typical problem areas that can be addressed naturally, and basic supplements that can help restore optimal health. Some Topics We Discussed: What is a diagnosis of type 2 diabetes? (6:08) What can impact your A1C levels? (6:45) What are ideal blood sugar levels? (8:59) What are the negative effects of elevated insulin levels? (13:17) What would Ed do if he was diagnosed as pre-diabetic? (14:55) What is the appropriate amount of protein to consume? (24:07) This podcast is powered by ZenCast.fm

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.    Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes 2.    Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy 3.     Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study 4.    Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes 5.    Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial   For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

On this episode of the Huddle, Kelly Postiglione Cook, RN, MSN, ANP-BC, CDCES, BC-ADM, and Sean Oser, MD, MPH, CDCES have a conversation about the importance of utilizing automated insulin delivery systems, like the iLet bionic pancreas, more widely in primary care. They provide insight into a study that evaluated the success of implementing use of the iLet bionic pancreas in a primary care setting, how the results illustrated that this technology can be more widely utilized in these settings, and the role diabetes care and education specialists can play in this work.This episode is sponsored by Beta Bionics. Episode References: Bionic Pancreas Research Group. Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. N Engl J Med 2022;387:1161-1172 DOI: 10.1056/NEJMoa2205225 Russell SJ, Selagamsetty R, Damiano E. Real-world efficacy of the iLet bionic pancreas in adults and children during the first eighteen months of commercial availability. Presented at the American Diabetes Association 85th Scientific Sessions, June 20-23, 2025, Chicago, IL.   Oser SM, Putman MS, Russel SJ, et al. Assessing the iLet Bionic Pancreas deployed in primary care and via telehealth: a randomized clinical trial. Clin Diabetes 2025; cd240104. https://doi.org/10.2337/cd24-0104 Oser C, Parascando JA, Kostiuk M, et al. Experiences of people with type 1 diabetes using the iLet bionic pancreas in primary care: A qualitative analysis. Clin Diabetes 2024 https://doi.org/10.2337/cd24-0060.  Sulik B, Postiglione Cook K, MacLeod J. Meals no longer need to be math problems: Shifting from precise carbohydrate counting to a continuum of carbohydrate awareness as automated insulin delivery advances. Diabetes Technology and Obesity Medicine 2025;1(1):79-83. DOI: 10.1089/dtom.2025.0010.  Resources:Learn more about Beta Bionics here: https://www.betabionics.com/Explore the latest in diabetes technology on danatech: danatech l Diabetes Technology Education for Healthcare ProfessionalsLearn more about a two-part course on integrating diabetes technology into primary care, put on through the collaboration of AANP and ADCES:Part 1: Integrating Diabetes Technology into Primary Care Part 1: Overview and Clinical ScenariosPart 2: Integrating Diabetes Technology into Primary Care Part 2: Interactive Case StudiesDive deeper into how diabetes technology can be incorporated into primary care on another recent episode of The Huddle featuring Kathryn Evans Kreider DNP, FNP-BC, BC-ADM, FAANP: https://thehuddle.simplecast.com/episodes/embracing-diabetes-technology-in-primary-care Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

ChatGPT recommends the Mediterranean diet as best for overall health. It groups red meat, sugar, and processed foods together as foods to avoid and recommends plant-based diets as superior. ChatGPT recommends avoiding keto and carnivore diets on a long-term basis. ChatGPT health advice comes from organizations such as the American Heart Association and the American Diabetes Association, which are heavily funded by certain industries and inherently biased. To lower cholesterol, ChatGPT claims you should lower dietary cholesterol, increase unsaturated fats, and replace animal proteins with plant proteins. Plants do not have complete protein, and if you reduce your dietary cholesterol, you could end up low in bile and vitamin D. Cholesterol is a vital component of your cell membranes, hormones, and brain.ChatGPT falsely claims that seed oils are not “that bad” when used in moderation. Balance and moderation allow you to continue eating bad food without worrying about the consequences. If you have a chronic disease, you can not simply “balance” your diet. If you have diabetes, you do not want to spike insulin with carbohydrates. ChatGPT recommends legumes and grains for people with diabetes and small, frequent meals. This advice would continue to spike insulin, and would not help reverse diabetes!When asked about diet and nutrition for people with chronic diseases, ChatGPT ignores powerful ways to drastically improve one's health, such as increasing vitamin D and fasting. It continues to recommend moderation for ultra-processed foods, claiming that it is safe and healthy for 20% of your daily calories to be ultra-processed.Dr. Eric Berg DC Bio:Dr. Berg, age 60, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the author of the best-selling book The Healthy Keto Plan, and is the Director of Dr. Berg Nutritionals. He no longer practices, but focuses on health education through social media.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Takeda has taken the lead in the race for a narcolepsy treatment with back-to-back phase III wins for their drug Oveporexton. Investors are eagerly awaiting breakthroughs in using psychedelics to treat depression. Ultragenyx faced a setback as the FDA rejected their gene therapy for Sanfilippo syndrome, citing manufacturing issues. The FDA is considering speeding up reviews for companies that promise to lower drug costs. Market reaction to recent readouts from Compass Pathways and Beckley Psytech/Atai in treatment-resistant depression shows the challenges psychedelic therapies must overcome for commercial viability. Rainin Micropro offers a solution to streamline NGS preparation with their 96-channel pipettor. The industry is also focused on precision diagnostics to support precision therapeutics in the future. AstraZeneca's Baxdrostat showed promising results in lowering blood pressure in a phase III trial. The ADA revealed R&D priorities for potential blockbuster obesity treatments. Relmada has abandoned development of a depression drug after three failed attempts.The challenges faced by psychedelic therapies in the treatment of depression are discussed, as recent readouts from Compass Pathways and Beckley Psytech/Atai in treatment-resistant depression have left investors wanting more. The market reaction highlights the hurdles psychedelic therapies must overcome to prove their commercial viability. Additionally, the importance of precision diagnostics in the development of next-generation precision oncology therapies is emphasized, stating that only with the adoption of digital imaging and AI-powered analysis will these therapies reach their full potential. The FDA has several important decisions lined up, including applications in lymphoma, rare diseases, and hormone deficiency, while the American Diabetes Association's annual meeting reveals R&D priorities for weight loss medicines. Topics discussed include Capricor's FDA rejection of a DMD cell therapy, the ALS community petitioning the FDA to reconsider Brainstorm's Nurown, and updates on COVID-19 vaccines and Alzheimer's drugs. Upcoming webinars and job opportunities in the biopharma industry are also included.

Send us a textHave you ever felt a twinge of guilt or pride or suspicion when asked to donate a dollar at the checkout counter? You're not alone. In this candid conversation, we'll dive into the real emotions, questions, and choices shoppers face when confronted with checkout charity requests. We'll unpack the convenience and collective impact of small donations (did you know Americans gave over $749 million at checkout counters in just one year??) while also examining the pressures, uncertainties, and desire for more intentional giving that many of us feel.Whether you say “yes” or “no” at the register, this episode will help you reflect on your own values and boundaries around generosity. Links from today's episode:That spare change you donate at checkout is adding up to millions for charities | NPR March 10, 2024https://www.npr.org/2024/03/10/1236458377/charity-roundup-donations-stores-fundraising#:~:text=That%20spare%20change%20you%20donate,up%20to%20millions%20for%20charities&text=Norton%20for%20NPR-,So%2Dcalled%20point%2Dof%2Dsale%20donations%20have%20sharply%20increased,charity%20have%20really%20taken%20off.&text=We%27ve%20all%20been%20there,giving%20actually%20dropped%20that%20year. ICYMI another episode you might enjoy:Episode#164 Three Ways to Be More Generous This YearLove the book recos on this show? Check out the Progressive Pockets Bookshelf:https://bookshop.org/shop/progressivepockets As an affiliate of Bookshop.org, Progressive Pockets will earn a commission if you make a purchase.Connect With Genet “GG” Gimja:Website https://www.progressivepockets.comTwitter https://twitter.com/prgrssvpckts Work With Me:Email progressivepockets@gmail.com for brand partnerships, business inquiries, and speaking engagements.Easy Ways to Support the Show1. Send this episode to someone you know! Word of mouth is how podcasts grow!2. Buy me a coffee (or a soundproof panel!) https://buymeacoffee.com/progressivepockets 3. Leave a 5 star rating and review for the show!//NO AI TRAINING: Any use of this podcast episode transcript or associated show notes or blog posts to “train” generative artificial intelligence (AI) technologies to generate text is expressly prohibited. This includes, without limitation, technologies that are capable of generating works in the same style or genre as this content. The author reserves all rights to license uses of this work for generative AI training and development of machine learning language models//Support the show

Jon Easter, RPh, joined Over the Counter to discuss the main ideas of his presentation from the American Diabetes Association's 85th Scientific Sessions.

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.    Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes 2.    Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension Meta-Analysis 3.    The Diabetes Prevention Program and Its Outcomes Study: NIDDK's Journey Into the Prevention of Type 2 Diabetes and Its Public Health Impact 4.    Comparative effectiveness of alternative second‐line oral glucose‐lowering therapies for type 2 diabetes: a precision medicine approach applied to routine data 5.    Phase 3 Trial of Semaglutide in Metabolic Dysfunction– Associated Steatohepatitis   For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Det kan være svært at bevare optimismen, når nogle af verdens stormagter ser ud til at stå på spring ved våbenarsenalet, men på den anden side ser de globale finansmarkeder dog ikke ud til at være gået helt i panik. Millionærklubben vejrer situationen og debatterer, om man som privat investor bør foretage sig noget. I studiet tjekker teknisk analytiker Lars Persson og Nordnets investeringsøkonom, Per Hansen, markedsåbningen, og med på en telefon fra ADA, American Diabetes Association-konferencen i Chicago, leveres sidste nyt om Novo Nordisk og Eli Lilly af Claus Johansen fra Global Health Invest. Sidst i udsendelsen får vi også et brandvarmt perspektiv på de globale oliemarkeder af Arne Lohmann Rasmussen fra Global Risk Management. Vært: Bodil Johanne GantzelSee omnystudio.com/listener for privacy information.

In this episode of the Elevate Care Podcast, David Norris, CEO of Affineon Health, discusses the transformative role of AI in healthcare, particularly in alleviating provider burnout and enhancing patient care. He shares insights from his extensive experience in healthcare technology, emphasizing the need for innovative solutions to support healthcare providers overwhelmed by administrative tasks. The conversation explores how AI can streamline processes, improve patient communication, and ensure data privacy, while also addressing the challenges of adoption among healthcare professionals. Norris highlights the importance of creating a supportive environment for providers and the potential for AI to revolutionize patient-provider relationships in the future.Chapters:00:00 AI in Healthcare: A New Era04:45 Addressing Provider Burnout with AI Solutions10:50 Operationalizing AI: Protocols and Provider Control15:56 The Future of AI in Patient Care21:58 Ensuring Data Privacy and Cybersecurity in AI25:50 Looking Ahead: The Future of AI in Healthcare About David Norris: Mr. Norris is a CEO, investor, board member, advisor, and serial entrepreneur. Utilizing his extensive experience and network, he works closely with investors and boards to accelerate the growth of high potential companies. He has extensive governance experience on a wide range of boards and board committees.As a serial entrepreneur, he has founded and built companies in a number of different industries and has extensive fund-raising experience, having raised capital from VC, private equity, strategic, angel, and debt sources.Mr. Norris has held leadership positions in a number of companies including: Co-founder and CEO, Affineon Health, Chairman and CEO, Element3 Health (acquired 2022), Co-founder, Co-Founder and CEO of MD Insider (acquired by Accolade (NASDAQ:ACCD)), Co-founder and CEO of BlueCava (acquired by IDify/Adstra), Co-Founder and CEO of OnRequest Images, Co-Founder and CEO of ObjectSpace (acquired), VP/General Manager at Casco Signal Ltd (acquired by Alstom (ALO:EN)), and Toccata Systems (acquired by Chilton).Mr. Norris has extensive international business experience, having lived and worked in Europe, Asia, and the United States. He is a regular speaker at industry conferences, has lectured at organizations such as Microsoft and the Harvard Business School, has appeared on business TV programs such as CNN, Bloomberg TV, and has been quoted in publications such as The Wall Street Journal and New York Times.Mr. Norris has won various awards, including the Ernst and Young Entrepreneur of the Year, the Inc. 500, and The Software 500. He supports a number of charities including the American Diabetes Association and the National MS Society. Mr. Norris sits on a number of boards and is a senior advisor to a number of companies. He is also a very active cyclist. Sponsors: Discover how WorkWise is redefining workforce management for healthcare. Visit workwise.amnhealthcare.com to learn more.About The Show: Elevate Care delves into the latest trends, thinking, and best practices shaping the landscape of healthcare. From total talent management to solutions and strategies to expand the reach of care, we discuss methods to enable high quality, flexible workforce and care delivery. We will discuss the latest advancements in technology, the impact of emerging models and settings, physical and virtual, and address strategies to identify and obtain an optimal workforce mix. Tune in to gain valuable insights from thought leaders focused on improving healthcare quality, workforce well-being, and patient outcomes. Learn more about the show here. Find Us On:WebsiteYouTubeSpotifyAppleInstagramLinkedInXFacebook Powered by AMN Healthcare

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.    Intensive Blood-Pressure Control in Patients with Type 2 Diabetes 2.    Cardioprotective Glucose-Lowering Agents and Dementia Risk A Systematic Review and Meta-Analysis 3.    A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes 4.    Screening for Metabolic Dysfunction–Associated Steatotic Liver Disease–Related Advanced Fibrosis 5.    Risk of Urogenital Infections in People With Type 2 Diabetes Initiating SGLT2i Versus GLP-1RA in Routine Clinical Care   For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Join us for a wildly entertaining and informative interview with renowned podiatrist Dr. David Alper as he shares the most jaw-dropping foot care mishaps he's encountered throughout his distinguished 30+ year career! Dr. Alper, who recently retired from his private practice in Belmont, MA, brings a wealth of experience as Emeritus Surgical staff at Harvard's Mt. Auburn Hospital and a member of the Board of Trustees of the American Podiatric Medical Association. His leadership extends beyond clinical practice—he served as President of the American Diabetes Association's New England Leadership Board for over 20 years and chaired the Belmont Board of Health for three decades. In today's interview, Dr. Alper takes us behind the scenes with stories that will make you laugh, cringe, and maybe even think twice about your summer footwear choices! From flip-flop disasters to beach glass emergencies, and patients who arrived at his clinic with situations you won't believe until you hear them. Whether you're planning a beach vacation or simply want to protect your feet this summer, you won't want to miss Dr. Alper's expert advice wrapped in these cautionary (and sometimes hilarious) tales from the frontlines of podiatric medicine. #FootHealth #SummerSafety #PodiatryStories #DrDavidAlper #BeachSafety #FootcareExpert

Dean's Chat hosts, Drs. Jeffrey Jensen and Johanna Richey welcome Dr. David Armstrong to the podcast.  This discussion wasn't about the "Diabetic Foot" as much as it was getting to know what makes the world leader in "Diabetic Foot" click.  His background and fascination with technology, intro to podiatry (he considered law) to transforming clinical opportunities at Kern Hospital and UT- San Antonio.   Dr. Armstrong is Distinguished Professor of Surgery and Neurological Surgery with Tenure at the University of Southern California. Dr. Armstrong holds a Master of Science in Tissue Repair and Wound Healing from the University of Wales College of Medicine and a PhD from the University of Manchester College of Medicine, where he was appointed Visiting Professor of Medicine. He is founder and co-Director of the Southwestern Academic Limb Salvage Alliance (SALSA).  Dr. Armstrong has produced more than 720 peer-reviewed research papers in dozens of scholarly medical journals as well as over 120 books or book chapters. He is founding co- Editor of the American Diabetes Association's (ADA) Clinical Care of the Diabetic Foot, now in its fourth edition.  Armstrong is Director of USC's National Science Foundation (NSF) funded Center to Stream Healthcare in Place (C2SHiP) which places him at the nexus of the merger of consumer electronics, wearables, and medical devices in an effort to maximize hospital-free and activity-rich days. Dr. Armstrong was selected as one of the first six International Wound Care Ambassadors and is the recipient of numerous awards and degrees by universities and international medical organizations including the inaugural Georgetown Distinguished Award for Diabetic Limb Salvage. In 2008, he was the 25th and youngest-ever member elected to the Podiatric Medicine Hall of Fame. He was the first surgeon to be appointed University Distinguished Outreach Professor at the University of Arizona. He was also the first podiatric surgeon to be selected as President of Faculty at Keck School of Medicine of USC. Furthermore, he was the first podiatric surgeon to become a member of the Society of Vascular Surgery, and the first US podiatric surgeon named fellow of the Royal College of Surgeons, Glasgow. He is the 2010 and youngest ever recipient of both the ADA's Roger Pecoraro Award and 2023 recipient of the ISDF's Karel Bakker Award, the highest awards given in the field. Dr. Armstrong is past Chair of Scientific Sessions for the ADA's Foot Care Council, and a past member of the National Board of Directors of the American Diabetes Association. He sits on the Infectious Disease Society of America's (IDSA) Diabetic Foot Infection Advisory Committee and is the US appointed delegate to the International Working Group on the Diabetic Foot (IWGDF). Dr. Armstrong is the founder and co-chair of the International Diabetic Foot Conference (DF-Con), the largest annual international symposium on the diabetic foot in the world. He is also the Founding President of the American Limb Preservation Society (ALPS), a medical and surgical society dedicated to building interdisciplinary teams to eliminate preventable amputation in the USA and worldwide. https://limbpreservationsociety.org/ https://bakodx.com/ https://bmef.org/ www.explorepodmed.org https://podiatrist2be.com/  

Join hosts Kym McNicholas, Emmy Award-winning journalist and CEO of Global PAD Association, and Dr. John Phillips, Interventional Cardiologist, as they welcome Dr. David Alper, podiatrist, to discuss critical summer foot health issues. In this episode, Dr. Alper shares entertaining stories about the biggest foot follies that occur during summer—from beach mishaps to BBQ blunders. But the conversation takes a serious turn as he reveals the hidden summer dangers for people with diabetes and peripheral artery disease (PAD). Learn essential strategies to protect vulnerable feet and prevent wounds that could lead to amputation. Dr. Alper brings decades of expertise as Emeritus Surgical staff at Harvard's Mt. Auburn Hospital and former Board of Trustees member of the American Podiatric Medical Association. His impressive background includes serving as President of the American Diabetes Association's New England Leadership Board for over 20 years and chairing the Belmont Board of Health for three decades. Whether you're concerned about your own foot health or caring for someone with circulation issues, this episode delivers valuable information that could help save limbs and lives this summer season. #FootHealth #DiabetesCare #PADAwareness #SummerSafety #HeartOfInnovation #peripheralarterydisease #padtreatment #diabetesfootcare #diabeticfoot #padsupportgroup #legcramps #legpaintreatment

Digital Impact and the Human Element of AI-Driven Transformation: Insights from Steve Lucas

Would you believe me if I told you that we could end chronic disease in 10 weeks? Watch this fascinating interview with best-selling author Nina Teicholz, Ph.D., who has been researching the dietary guidelines for over 2 decades. SUBSCRIBE TO NINA'S SUBSTACK HERE: https://unsettledscience.substack.com...Please join me in welcoming Nina Teicholz! Nina explains that a low-carb ketogenic diet is the best way to support disease reversal. There are over 100 clinical trials supporting that type 2 diabetes can be reversed in as little as 10 weeks. Hypertension, cardiovascular risk factors, non-alcoholic fatty liver disease, and other chronic diseases can potentially also be reversed with dietary changes.The reversal rate of type 2 diabetes with the standard of care from doctors is 0.1%. In clinical trials with patients following a keto diet, the reversal rate is more than 50%! Insulin manufacturers and other drug companies primarily fund the American Heart Association and American Diabetes Association, so they are subject to direct conflicts of interest. Doctors have been taught to recommend low-fat diets, and there are countless baseless claims that keto is dangerous. Dietary guidelines significantly influence most Americans. By law, all federal food programs are required to follow these guidelines. Health professionals also use them as the gold standard in nutrition. However, many conflicts of interest are involved in these guidelines, including ties to both Big Food and Big Pharma. Giving accurate dietary guidelines to the American public is the best way to combat chronic disease.To get into a healthy state of ketosis, you should eat eggs, dairy, meat, shellfish, vegetables, and low-sugar fruits. Carbohydrates trigger hunger. Without glucose, your body can access your fat stores for energy between meals.

This episode is brought to you by  Bon Charge and Momentous. We used to think circadian rhythm only applied to sleep. But emerging science has revealed a link between our circadian rhythm and metabolism, cognition, risk for chronic diseases, and many other crucial aspects of our health. Our biology was designed to live in sync with a natural light-dark cycle, but modern-day society has disrupted this natural balance.  Today on The Dhru Purohit Show, we're revisiting one of our favorite episodes with Dr. Satchin Panda. Dr. Panda dives deep into his groundbreaking circadian biology research and shares how leveraging your circadian rhythm can dramatically improve your sleep, lower your risk of chronic disease, and improve your cognitive function. They also discuss how time-restricted eating, exercise, and light can be used to help program your circadian rhythm and why it's especially important for shift workers to take advantage of these tools.  Dr. Panda is pioneering circadian biology research. He is a professor at the Salk Institute for Biological Studies, a Pew Biomedical Scholar, founder of the UC San Diego Center for Circadian Biology, and recipient of the Julie Martin Mid-Career Award in Aging Research. Dr. Panda has spoken at conferences around the world about his work on circadian rhythms and diabetes, including Diabetes UK, the American Diabetes Association, the Danish Diabetes Association, and the professional diabetes societies of Europe and Australia. In this episode, Dhru and Dr. Panda dive into: Why late-night eating is so detrimental to our health (2:15) Organ systems that have a circadian rhythm (8:24) Common ailments that could be related to circadian rhythm disturbances (14:11) Night-shift work and cancer risk (20:19) How poor sleep perpetuates bad food choices (27:00) What happens in the body when you rely on an alarm clock (44:01) Why you need to accumulate sleep debt for better sleep (51:25) Time-restricted eating and sleep (1:00:40) How to combat fragmented sleep (1:15:35) The best time to work out (1:55:50) The link between exercise and cancer (2:07:55) Positive changes for better sleep health on a global scale (2:17:20) Strategies for night-shift workers to combat circadian rhythm disruption 02:45:10) Dr. Panda's research in firefighters (2:48:46) Tips for optimizing your circadian rhythm (3:14:20) Where to follow and support Dr. Panda's work (3:27:50) Also mentioned in this episode: The Circadian Code: Lose Weight, Supercharge Your Energy, and Transform Your Health from Morning to Midnight The Circadian Diabetes Code: Discover the Right Time to Eat, Sleep, and Exercise to Prevent and Reverse Prediabetes and Diabetes Download the MyCircadianClock app Try This: 6 Crazy Facts About Sleep Try This: How Exercise Helps Fight Cancer For more on Dr. Satchin Panda, follow him on Twitter @SatchinPanda, Instagram @satchin.panda, or his Website. This episode is brought to you by Bon Charge and Momentous. Right now, BON CHARGE is offering my community 15% off; just go to boncharge.com/DHRU and use coupon code DHRU to save 15%. Optimize your energy and mental clarity with the Momentous Three: Protein, Omega-3s, and Creatine made by and used by the best. Go to livemomentous.com and enter promo code DHRU to get 20% off any order.  Learn more about your ad choices. Visit megaphone.fm/adchoices